EFFECTS OF ACUTE AND CHRONIC TREATMENT WITH 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND THE CANNABINOID RECEPTOR AGONIST WIN55,212-2 ON BEHAVIOUR AND COGNITION IN RATS by Schulz, Sybille
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECTS OF ACUTE AND CHRONIC TREATMENT WITH 
3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) 
AND THE CANNABINOID RECEPTOR AGONIST WIN55,212-2 
ON BEHAVIOUR AND COGNITION IN RATS 
 
 
 
Aus dem Institut für Hirnforschung, Abteilung Neuropharmakologie, 
Zentrum für Kognitionswissenschaften 
 
 
DISSERTATION 
 
 
Zum Erlangen des akademischen Grades eines Doktors der Naturwissenschaften  
(Dr. rer. nat.) 
 
 
Vorgelegt dem Fachbereich 2 (Biologie/Chemie) der Universität Bremen 
 
 
von 
 
 
SYBILLE SCHULZ 
 
 
Im März 2012 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Gutachter: Prof. Dr. Michael Koch 
2. Gutachter: Prof. Dr. Ursula Dicke  
 
Kolloquium: 15.5.2012 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Declaration of authorship
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Declaration of original authorship 
 
 
I hereby declare that the thesis submitted only contains my original work except where indicated 
and properly acknowledged. Some parts of the practical work have been carried out by students 
under my supervision. No other sources or materials where used. 
 
 
 
 
 
Sybille Schulz 
 
 
 
Bremen, März 2012 
 
 
 
 
  
 
 
 
 
 
Publications 
 
 
 
List of publications 
 
 (*) indicates publications or manuscripts included in this thesis. Articles have been published or 
submitted to international scientific journals. 
 
 
 
Articles 
 
* Schulz, S (2011). MDMA & Cannabis: A Mini-Review of Cognitive, Behavioural and 
Neurobiological Effects of Co-consumption. Current Drug Abuse Reviews, 4(2):81-6. 
 
* Schulz, S; Gundelach, J; Svärd, HK; Hayn, L; Koch, M (2012). Acute co-administration of the 
Cannabinoid receptor agonist WIN 55-212,2 does not influence 3,4-
methylenedioxymetamphetamine (MDMA)-induced effects on effort-based decision making, 
locomotion, food intake and body temperature. Substance Abuse (under review). 
 
 * Schulz, S; Becker, T; von Ameln-Mayerhofer, A; Nagel, U; Koch, M (2012). Chronic co-
administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or adulthood 
reverses 3,4-methylenedioxymetamphetamine (MDMA)-induced deficits in recognition memory but 
not in effort-based decision making. Behavioural Pharmacology (under review). 
 
Crunelle, CL; Schulz, S; de Bruin, K; Miller, ML; van den Brink, W; Booij, J (2010). Dose-
dependent and sustained effects of  varenicline on dopamine D2/3 receptor availability in rats. 
European Neuropsychopharmacology, 21(2):205-10. 
 
Crunelle, CL; van de Giessen, E; Schulz, S; Vanderschuren, LJ; de Bruin, K; van den Brink, W; 
Booij, J (2011). Cannabinoid-1 receptor antagonist rimonabant (SR171416) increases striatal 
dopamine D2 receptor availability. Addiction Biology, doi: 10.1111/j.1369-1600.2011.00369. 
 
 
 
 
 
 
 
 
 
 
Publications 
 
Poster presentations 
 
International Symposium on Drugs of Abuse, 28-29 July 2008, Sao Miguel, Azores, Portugal. 
Schulz, S; Nagel, U; von Ameln-Mayerhofer, A. Repeated administration of MDMA and MDMA 
derivatives in rats: behavioural sensitization and neurotoxic effects. 
 
European Graduate School in Addiction Research (ESADD), 2nd seminar week, October 2009. 
Schulz, S. Psychotropic Pharmaceuticals in Germany. The „silent“ addiction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index
 
 
 
Index 
General Introduction 2 
MDMA 2 
History and Use 2 
Prevalence 3 
Acute effects 3 
Risks, long-term effects & impairments 4 
Pharmacology 7 
Cannabis 12 
History and Use 12 
Prevalence 13 
Risks, long-term effects & impairments 15 
Pharmacology 18 
Decision making 20 
Influence of MDMA 22 
Influence of Cannabis 23 
Aim of the thesis and summaries 25 
Review 25 
Study 1 25 
Study 2 26 
MDMA & Cannabis: A Mini-Review of Cognitive, Behavioral, and 
Neurobiological Effects of Co-consumption 27 
Abstract 27 
Introduction 28 
MDMA+Cannabis: effects on higher cognitive functions 29 
MDMA+Cannabinoid agents: behavioral effects & neurobiological interactions 31 
Conclusion 35 
Acute Co-administration of the Cannabinoid Receptor Agonist WIN55-212,2  
does not influence 3,4-methylenedioxymetamphetamine (MDMA)-induced 
Effects on Effort-based Decision making, Locomotion, Food intake and 
Body temperature 36 
Abstract 36 
Introduction 37 
Index
 
 
 
Materials & Methods 39 
Animals 39 
Drugs 39 
Behavioural tests 39 
Data analysis 41 
Results 41 
Effort-based decision making 41 
Body temperature 42 
Locomotor activity and exploratory behaviour 43 
Food preference test 46 
Discussion 46 
Conclusion 51 
Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 
during puberty or adulthood reverses 3,4-methylenedioxymetamphetamine 
(MDMA)-induced deficits in recognition memory but not in effort-based 
decision making 52 
Abstract 52 
Introduction 53 
Materials & Methods 56 
Animals 56 
Drugs 56 
Treatment 56 
Behavioural tests 57 
Statistical analysis 59 
Results 59 
Object recognition test 59 
Effort-based decision making 61 
Delay-based decision making 62 
Locomotion 63 
Body weight 64 
Discussion 65 
Conclusion 68 
Histological verification of the density of myelinated axons following chronic treatment with 
MDMA, WIN55,212-2, or their combination 69 
Method: Gold-chloride staining 69 
Results 69 
Discussion 71 
Index
 
 
 
General discussion 73 
MDMA 73 
WIN55,212-2 74 
MDMA & WIN 75 
Conclusion 76 
Deutsche Zusammenfassung 78 
Einleitung 78 
Review 79 
Studie 1 80 
Studie 2 81 
Fazit 81 
References 83 
Acknowledgements 99 
 
 
 
 
Index
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Introduction
 
 
1 
General Introduction 
 
MDMA (3,4-methylenedioxymetamphethamine, “ecstasy”) is one of the most popular illicit 
recreational drugs among young adults. However, the underlying neurobiological mechanisms 
responsible for the physiological, behavioural and psychological effects, as well as the influence on 
cognitive functions such as memory and decision making are still not fully examined. Furthermore, 
if and to what extend this drug has neurotoxic properties is debated. Most ecstasy users are 
polydrug users, and the majority concomitantly consumes cannabis. 
 
Cannabis is the most frequently consumed illegal psychoactive drug world wide. While cannabis 
products are generally perceived as “soft drugs” and their potential medical usefulness is 
progressing, cognitive impairments and long-term alterations in the brain, especially following 
prolonged and heavy use in adolescence, are observed. 
 
This thesis investigates the influence of MDMA and the synthetic cannabinoid receptor agonist, 
WIN55,212-2 (WIN), on different forms of decision making, memory function, locomotor activity 
and physiological parameters such as body temperature and food intake. Within both an acute as 
well as chronic systemic administration schedule, effects of each substance alone as well as their 
combination is tested in order to mimic co-consumption of these drugs. Within chronic treatment, 
adult as well as pubertal rats and their respective brain myelination levels are examined to 
determine vulnerable periods of drug consumption or age-related differences. 
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2 
MDMA 
 
History and Use 
 
MDMA (3,4-methylenedioxymetamphetamine) is a synthetic ring-substituted amphetamine 
derivative (Fig.1). Originally, it was a by-product of the synthesis of the haemostatic drug 
hydrastinine in 1912 by the German chemist Anton Köllsch (Benzenhofer and Passie, 2006). 
Mentioned as one of many chemical intermediate products, it was patented in 1912 to the 
pharmaceutical company MerckKGaA (Freudenmann et al., 2006) The first systematic 
pharmacological tests with the substance now called MDMA, transformed to a hydrochlorid salt, 
are documented in 1927. During the 1950s, the US military clandestinely tested MDMA, 
presumably for its toxic effects or as novel interrogation method (Shulgin, 1990). Official studies in 
animals and humans emerged another 30 years later, and only in the 1960s, its psychoactive 
properties were scientifically studied and reported (Benzenhofer and Passie, 2006). MDMAs’ 
potential for use in psychotherapeutic settings, enhancing interpersonal relationships due to its 
empathogenic and entactogenic properties, was suggested by the American chemist Alexander 
Shulgin in the late 1970s (Benzenhofer and Passie, 2010). Therapists applied MDMA during their 
sessions until it was restricted by the drug enforcement administration (DEA) in 1985. Today its 
application in treatment of post-traumatic stress disorder (PTSD)  is still debated (Doblin, 2002). 
 
 
 
 
 
 
 
Fig.1: Chemical structure of 3,4-methylenedioxymetamphetamine (MDMA). MDMA is a racemate, 
consisting of a 1:1 mixture of the two enantiomeres R(-) (above) and S(-) (below). S(-) MDMA has a half-life 
of about 4.8 hours, and is associated with subjective and psychomotor effects. R(-) MDMAs half-life is longer 
(14.8 hours), thus thought to be involved in the consequences regarding mood and cognitive performance 
which last longer than the acute effects  (Pizarro et al., 2004). 
 
MDMA is classified as a schedule I drug in Germany and most other countries, meaning it is illegal 
to buy, sell, or possess, except for strictly limited research or medical purposes (UNODC, 2010).  
Since it was not regulated under law until 1985, the substance started to become widely distributed 
and was used as recreational drug mainly at clubs and dance parties among all social classes 
during the 1980s (Benzenhofer and Passie, 2006). Paralleling the emergence of the rave culture, 
popularity of MDMA increased rapidly during the 1990s and today it is the second most commonly 
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3 
used illegal psychoactive drug world wide (after cannabis). The WHO estimates the global illegal 
production of MDMA between 55 and 133 tons annually, with most manufacture taking place in 
North America and Europe, followed by Brazil and Argentina, Oceania and Russia (UNODC, 
2010).  
 
 
 
 
 
 
 
 
 
Fig.2: Picture of ecstasy pills (retrieved from www.erowid.com) 
 
 
MDMA is most commonly sold in the form of "ecstasy" tablets and taken orally, rarely the powder 
form is snorted. In Europe, most ecstasy tablets contain MDMA as their main psychoactive 
ingredient (EMCDDA, 2010), however other substances (e.g., other amphetamines (including MDE 
or MDA), ephedrine, paracetamol, caffeine) have also been found in tablets sold as “ecstasy” 
(Sherlock et al., 1999).  In recent years, purity in terms of MDMA content has been reported to lie 
between 90-100% (Parrott, 2004) (Fig.2). In the following, the term “ecstasy” will be used when 
referring to the pills taken by human drug users, whereas “MDMA” refers to the pure chemical 
compound found in ecstasy tablets.  
 
Prevalence 
 
The prevalence of use has stayed relatively constant within the last two decades. Recent 
representative surveys in western countries found that 3.5% of 15-34 year olds consumed ecstasy 
during the last year, and 8.4% report life time prevalence (Degenhardt et al., 2010) (1.7 and 5.8% 
in European countries, respectively (EMCDDA, 2010)). Prevalence is higher in younger adults and 
in males compared to females. Most past-year users took ecstasy tablets intermittently (once or 
twice a year) and only a minority (5-10%) consumed ecstasy on a monthly or weekly basis. The 
United Nations estimate around 9 million current users world wide. 
Acute effects 
 
Psychological effects described by users include increased euphoria, energy, empathy and mood, 
and awareness of sensations, feelings of comfort and belonging to others, hallucinations, as well 
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4 
as decreased anxiety upon consumption. Acute adverse physiological effects include decreased 
appetite, increased heart rate and blood pressure, sweating, bruxism, dry mouth, hyperthermia and 
insomnia. Difficulties concentrating, anxiety, as well as psychological addiction have been 
reported. Most users also report negative after-effects 24 hours to one week following ecstasy 
consumption (Green et al., 2003). In laboratory animals, dose-dependent alteration of body 
temperature, leading to hyperthermia (or hypothermia, dependent on the ambient temperature), 
increased heart rate, vasoconstriction and anxiogenesis (at low doses), hyperactivity upon acute 
administration of MDMA, and increasing locomotor activity in response to repeated administration 
(termed behavioural sensitization), are well known effects (Green et al., 2003). MDMA does have 
reinforcing properties, as rats voluntarily and repeatedly self-administer doses up to 1mg/kg 
intravenously (i.v.) (Schenk, 2009). These effects can be ascribed to the MDMA-induced 
stimulation of neurotransmitter systems, especially serotonin (5-HT) and dopamine (DA), in the 
brain. 
Risks, long-term effects & impairments 
 
Acute adverse side effects range from minor disturbances of the central and autonomous nervous 
system such as confusion, irritability, hypertension or bruxism to major negative and potentially life-
threatening effects like severe hyperthermia (up to 42°C), cardiovascular collapse, arrythmias and 
rhabdomyolysis (breakdown of skeletal muscle) (Green et al., 2003). Statistics from the USA and 
EU drug monitoring centres show an increase in ecstasy-related emergency room visits and 
deaths during the last 20 years, paralleling increased use of the drug. Deaths involving only MDMA 
are rare and mostly occur in first time users (UNODC, 2010; EMCDDA, 2009). 
Furthermore, delayed and possibly long-lasting neuropsychiatric effects have been found in heavy 
and/or chronic ecstasy-users. These include panic disorder, aggressive behaviour, major 
depressive disorder, and deficits in memory and cognitive functioning. While some traits, like 
impulsivity, sensation seeking or vulnerability to depression may be precursors, rather than 
consequences of ecstasy use (Butler and Montgomery, 2004), most long-term or retrospective 
studies so far have supported the idea that ecstasy has deleterious effects on certain brain 
functions. In particular, deficits in various memory domains (working, delayed, associative and 
verbal memory tasks), learning, executive control and attention have been shown (Gouzoulis-
Mayfrank et al., 2000; McCann et al., 1999; Morgan et al., 2006; Rodgers, 2000; Morgan et al., 
2002; Jager et al., 2008). Some studies found only small effects of ecstasy use on neurocognitive 
performance, or attributed deficits to concomitant use of other drugs, especially cannabis (Halpern 
et al., 2011; Medina and Shear, 2007; Daumann et al., 2004). Furthermore, altered activity in 
frontal and hippocampal brain areas was found in ecstasy users (Daumann et al., 2005; Jacobsen 
et al., 2004). However, since MDMAs’ popularity only emerged 20 years ago, there are only few 
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well-controlled longitudinal studies looking at long-term impairments in mood and cognitive 
functions. 
In rats, MDMA-administration is associated with long-term consequences including impaired 
thermoregulation at high ambient temperatures (Mechan et al., 2001), increased anxiety, and 
deficits in social interaction. Increased anxiety, measured in emergence, elevated plus maze and 
social interaction tests, was evident up to three months after moderate doses of MDMA (5mg/kg) 
(Gurtman et al., 2002; McGregor et al., 2003). Lasting impairments in cognitive functioning were 
evident, too. For example, rats treated with an intermittent schedule during puberty later displayed 
deficits in short-term or working memory, measured with an object recognition task, and spatial 
learning and memory, measured in a Morris water maze task (Capela, 2009).  
These long-term effects may correlate to MDMA-induced reduction in serotonergic functioning (see 
Excursion 2: Neurotoxicity). 
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Fig.3: Schematic illustration of 
distribution and projections of 5-HT 
neurons a) in the human brain b) in the rat 
brain. Distribution of 5-HT neurons is similar 
to humans in that a rostral group of neurons 
(B7-9) gives rise to ascending projections 
terminating in the forebrain, whereas 
descending projections originate from a 
caudal group (B1-3). In addition, an 
intermediate group of neurons (B4-6) 
projects serotonergic fibres along ascending 
and descending pathways (adapted from 
Cools, 2007). 
 
Excursion 1: The Serotonergic System  
Serotonin (5-hydroxytryptamine, 5-HT) is one of the main monoamine neurotransmitters in the brain. It 
modulates numerous processes in the central nervous system (CNS), including mood, anxiety, sleep, 
appetite, cognition and reward systems. In the human brain stem, cells from the rostral raphe nuclei, 
including dorsal and medial raphe nuclei, give rise to ascending serotonergic fibres, projecting to forebrain 
regions including cortex, thalamus and limbic structures, whereas caudal raphe nuclei are the origin of 
descending and cerebellar projections (Fig.3). The first and rate limiting step of 5-HT synthesis is 
hydroxylation of tryptophan to 5-hydroxytrypthophan (5-HTP) by the enzyme tryptophan hydroxylase. 5-HTP 
is further decarboxylated to 5-HT by L-amino-acid decarboxylase. Subsequently, 5-HT is transported into 
intracellular storage vesicles by a vesicular monoamine transporter (VMAT). Upon arrival of an action 
potential, a Ca2+-mediated process leads to release of 5-HT from the terminals of the presynapse. 5-HT 
binds to seven main classes of 5-HT receptors (5-HT1- 5-HT7), which are further divided into 14 distinct 5-HT 
receptor subtypes based on their structural, pharmacological and chemical properties (Barnes and Sharp, 
1999). All 5-HT receptors consist of seven transmembrane domains. Except for 5-HT3, which is a ligand-
gated ion channel, all receptors are members of the G-protein coupled (metabotropic) receptor family. 
Binding of 5-HT to the extracellular site activates a G-protein, which initiates intracellular second messenger 
signalling. 5-HT1 receptors are linked to inhibitory G proteins, whereas activation of 5-HT2, 5-HT4, presumably 
5-HT5 and 5-HT7 initiates stimulatory signalling. Action of 5-HT is terminated by serotonin plasma membrane 
transporter (SERT)-mediated reuptake into the presynapse or metabolization to 5-hydroxyindoleacetic acid 
(5-HIAA) by monoamine oxidase. Considering the differential characteristics of the 5-HT receptor classes 
(including inhibitory autoreceptors (e.g., 5-HT1A) as well as excitatory post-synaptic receptors (e.g., 5-
HT2A/C)), and the abundant distribution of serotonergic neurons across the CNS, the complexity of 
serotonergic involvement in physiological as well as behavioural, emotional, and cognitive processes 
becomes obvious. 
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Pharmacology  
 
Pharmacodynamics 
 
MDMA affects the central nervous system by influencing neurotransmitter systems. More 
specifically, it acts as an indirect monoamine agonist. Early studies in laboratory animals 
demonstrate increased levels of serotonin (5-HT), to a lesser extent dopamine (DA), and 
noradrenaline (NA) following administration of MDMA (Gudelsky and Nash, 1996; Yamamoto and 
Spanos, 1988; Fitzgerald and Reid, 1990). More recently, inhibition of the monoamine transporters 
(SERT, DAT, NAT) was found responsible for increases in extracellular monoamines (Capela et 
al., 2009). In comparison to other amphetamines, MDMA has increased potency to inhibit SERT, 
while its potencies to inhibit DAT and NAT are reduced. Fig.5 details mechanisms by which MDMA 
increases extra- and intracellular 5-HT levels. Some of its behavioural effects have also been 
ascribed to indirect activation of the DA system (Bankson and Cunningham, 2001). In addition to 
binding to monoamine receptors (subtypes 5-HT2, 5-HT1, D1 and D2), MDMA exerts its effects by 
interaction with various other neurotransmitter systems. For example, MDMA displays affinity to 
adrenergic, histaminergic, nicotinic and muscarinic acetylcholine receptors, leading to increased 
signal transduction, thereby contributing to the cardiovascular and autonomic side effects as well 
as abuse-potential (Capela et al., 2009). 
 
Pharmacokinetics 
 
Due to easy diffusion across cell membranes, the lipophilic molecule MDMA is rapidly absorbed in 
several tissues. Controlled studies in humans demonstrated that the maximal plasma 
concentration of MDMA is reached between 1.5-3 hours after oral ingestion. The increase of 
concentration is not proportional to the dose ingested, indicating non-linear pharmacokinetics 
(Yang et al., 2006). This is due to saturated hepatic metabolism of MDMA, as well as interaction of 
its metabolites with enzymes involved in the catabolism. MDMA interferes with its own metabolic 
pathway by inhibiting the hepatic CYP2D isoenzyme, which regulates demethylenation of MDMA 
during the metabolic process in humans (CYP2D6) as well as in rats (CYP2D1) (de la Torre et al., 
2000; Delaforge et al., 1999; Heydari et al., 2004). This autoinhibition lasts at least 24 hours, and is 
accompanied by increased pharmacological, physiological and subjective effects after repeated 
dosing (Farre et al., 2004). In humans, about 80% of MDMA is transformed metabolically through 
the liver, 20% is excreted unaltered in urine. In rats, the rate of metabolism is almost linear up to a 
dose of 10mg/kg. Higher doses produce non-linear increases in the concentration in the brain and 
plasma levels. Notably, brain concentrations are generally much higher for doses of 20 or 40mg/kg 
compared to plasma concentrations, because MDMA accumulates in 5-HT cells (see Fig.5).  
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Fig.5: Pharmacological action of MDMA on a serotonergic synapse. MDMA induces increases in 5-HT 
concentrations via distinct mechanisms: [1] entering the cell by binding to the SERT, [2] disruption of 
vesicular storage, thereby increasing cytoplasmic concentrations of 5-HT, [3] inhibition of tryptophan 
hydroxylase (TPH), [4] inhibition of monoamine oxidase, the enzyme responsible for 5-HT degradation, [5] 
reversing the direction of SERT, thus more 5-HT molecules exit the cell. The first two and the fifth 
mechanisms involve substrate binding of MDMA to the monoamine transporters and reversing their actions, 
namely the SERT and the vesicular monoamine transporter (VMAT). Furthermore, MDMA directly binds to 
the postsynaptically located 5-HT2 receptor subtype 5-HT2A [6], which accounts for its hallucinogenic property 
and hyperthermic effect
 
(adapted from Capela, 2009). 
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Excursion 2: Neurotoxicity of MDMA 
Neurotoxicity is defined as any adverse effect which disrupts, impairs, or impedes activity of neuronal cells. 
This can take place by affecting the functionality (e.g., loss of signalling ability) or damaging physical 
structures (e.g., deterioration of cells), and effects may be permanent or reversible (Erinoff, 1995). Despite 
two decades of studies in humans and laboratory animals, the degree of MDMA-induced neurotoxicity and 
the underlying mechanisms remain inconclusive (Capela et al., 2009).  
Some studies suggest that MDMA leads to general neuronal cell death (apoptosis) across brain regions, for 
example, in the cortex, thalamus, and hippocampus. Acutely, MDMA leads to an increased efflux of both 5-
HT and DA, however, most experimental data points to or  is restricted to effects on the serotonergic system. 
High doses of MDMA given repeatedly (20mg/kg/day, for 10 days) selectively reduced 5-HT levels in the 
forebrain of laboratory rats, while DA levels remained the same or increased 4 weeks after treatment 
(Mayerhofer et al., 2001). In neuroimaging studies with recreational MDMA users, a reduction of SERT, but 
not DAT, density was evident (Schouw et al., 2011; McCann et al., 2008). In the cerebrospinal fluid of MDMA 
users, reduced levels of 5-HIAA, the main metabolite of 5-HT, was found, and this reduction was more 
severe the higher the average dose(s) of MDMA (McCann et al., 1994; McCann et al., 2008).  
Doses and route of administration differs between human and animal studies, and most administration 
schedules in rats possibly relate to rather heavy MDMA-consumption in humans. Furthermore, differences in 
metabolism and polydrug use in humans make a direct comparison of neurotoxic properties of MDMA 
difficult. However, animal experiments allow for more detailed studies regarding the underlying mechanisms 
of pure MDMA administration, which may also relate to humans. In rats and non-human primates, 
neurochemical markers for 5-HT, 5-HIAA, and SERT have shown decreased levels of the neurotransmitter 
and reduced availability of its transporter in various brain regions, specifically in the neocortex, striatum, and 
hippocampus, as well as in cerebrospinal fluid. Degeneration of serotonergic axon terminals, mainly fine 
diameter fibres arising from the dorsal raphe nuclei, has been postulated (Capela et al., 2009).  
 
Mechanisms 
There are many theories and experimental indications about the underlying mechanisms of MDMA-induced 
neurotoxicity. In the following, three major hypotheses are described in detail. 
 
Hyperthermia 
There is a positive correlation between serotonergic neurotoxicity of MDMA and hyperthermia. In a hot 
environment (30°C) MDMA induced greater increase in efflux of DA as well as 5-HT, and depletion of 5-HT 
and 5-HIAA levels was more pronounced in temperatures above 26°C (Malberg and Seiden, 1998; O'Shea 
et al., 2005). Neuronal cortical cells incubated with added MDMA at 40°C showed significantly higher rates of 
cell death compared to those at 36.5°C (Capela et al., 2006). However, rats in cold environments (10°C) still 
show reduced 5-HT levels. In humans, MDMA promotes increase of body temperature regardless of the 
ambient temperature (Freedman et al., 2005). Furthermore, drugs with a hypothermic effect, for example 5-
HT2A and glutamate receptor antagonists, attenuate, whereas drugs inducing hyperthermia enhance, MDMA-
induced neurotoxicity. Some protective mechanisms (e.g., inhibition of nitric oxide synthase) have been 
shown to be effective by inducing hypothermia or counteracting hyperthermia. Therefore, the importance of  
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hyperthermia in the toxic process is firmly supported. Hyperthermia enhances, but is not necessary for, or 
the only cause of, neurotoxicity. At the same time, a hyperthermic environment might increase the 
metabolizing activity of enzymes, thus increasing the rate of production of possibly toxic metabolites of 
MDMA (Capela et al., 2006). 
 
Metabolites of MDMA 
Direct injection of MDMA into the brain of rats does not cause serotonergic neurotoxicity seen after 
peripheral administration (Monks et al., 2004). MDMA metabolism leads to the formation of nine potentially 
highly reactive main metabolites, thus MDMA metabolites are prominent candidates for neurotoxic potential. 
Generally, in vivo as well as in vitro studies show that the further advanced the metabolite, the more direct 
and faster are its toxic effects. In this line, alpha-MeDA (the major metabolite of MDMA in rats), produced 
long-term depletion 5-HT in the cortex, hippocampus, and striatum of rats when administered 
subcutaneously (s.c.), and in neuronal cell cultures when incubated for 48 hours. On the other hand, further 
metabolites 5-(GSH)-alpha-MeDA and 5-(NAC)-alpha-MeDA had no effect when administered 
intracerebroventricularly (i.c.v.), but caused long-term 5-HT depletion when directly administered intrastriatal 
or intracortical, as well as substantial neuronal cell death already during short incubation time (6 hours) 
(Capela et al., 2009). Further oxidization of these metabolites leads to the formation of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS), which promote oxidative stress that can ultimately lead 
to neuronal cell death. Antioxidants have been shown to reduce MDMA-induced neurotoxicity, thus 
confirming the notion of oxidative stress being a major contributor to neurotoxicity. This hypothesis is further 
supported by decreased 5-HT neurotoxicity following inhibition of SERT by flouxetine, which prevents entry 
of MDMA or its reactive metabolites into the cell. 
 
Monoamine oxydase (MAO)-mediated metabolism 
MAO deaminates monoamine neurotransmitters inside the cells, a process during which ROS are formed. 
The excessive extravesicular release of 5-HT, and increase in extracellular concentrations of DA and NE by 
MDMA leads to increased ROS formation, presumably damaging mitochondria, eventually leading to 
degradation of the nerve terminal. Furthermore, MAO-mediated metabolism of 5-HT and DA results in 
reactive aldehyde intermediates before conversion to more stable DOPAC and 5-HIAA. Pharmacological 
inhibition of MAO-B, which deaminates 5-HT, has been proven to be protective against MDMA-induced 
neurotoxicity due to oxidative damage (Capela et al., 2009). 
 
Current controversy 
Early studies using silver staining as a marker for neuronal cell death found increased staining of axons, 
dendrites and few cell bodies in frontal brain areas following MDMA-administration (Jensen et al., 1993). 
However, doses used in these experiments were extremely high (25-150mg/kg), and nowhere near 
behaviourally relevant or commonly ingested doses by humans. Studies investigating the long-term effect of 
a neurotoxic MDMA treatment regime demonstrated region dependent recovery of serotonergic markers in 
most brain areas after one year, however some brain areas remained denervated or abnormally innervated 
with nerve fibre fractions (Scanzello et al., 1993; Sabol et al., 1996). These observations have led to the  
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assumption of permanent loss of serotonergic cells, specifically axon terminals due to MDMA administration. 
However, the problem with neurochemical markers of the serotonergic system is that they provide an indirect 
measure of functioning, and do not evidence structural loss of neurons. The most parsimonious conclusion 
from these studies is that at very high doses, MDMA leads to general neuronal degradation, not restricted to 
5-HT neurons. Some recent studies tried to disentangle structural from functional loss. For example, 
depletion of 5-HT, but not SERT or changes in glial fibrillary acidic protein (GFAP), a marker for neuronal 
degeneration, were found after MDMA administration (single or repeated administration of 7.5-20mg/kg) 
(Wang et al., 2004; Baumann et al., 2007; Pubill et al., 2003). In contrast, the specific serotonergic 
neurotoxin 5,7DHT decreased 5-HT and SERT expression and increased GFAP (Wang et al., 2005). 5-HT 
levels could be restored two weeks later in 5,7DHT treated animals. Neuronal axotomy, either by the known 
5-HT neurotoxin or presumably by MDMA, does not seem to prevent serotonergic recovery. Recent 
experimental data using Western blot technique demonstrates that SERT protein content in the striatum and 
nucleus accumbens is not changed, but SERT was relocated into cellular structures after MDMA treatment 
(Kivell et al., 2010). Thus, neurochemical markers attaching to extracellular SERT would reveal that its 
binding availability is reduced, while in fact, temporary or permanent relocation took place. Long-lasting 
behavioural effects in animals, for example, increased anxiety, and cognitive impairments in humans, such 
as memory function, have been shown in the absence of 5-HT or SERT depletion (McGregor et al., 2003; 
Thomasius et al., 2006), suggesting that functional changes at the receptor or transporter level may be 
sufficient to elicit long-term consequences. These results add to the current debate about the neurotoxicity of 
MDMA in that changes on the 5-HT system might be restricted to depletion of 5-HT and decreased 
availability of SERT in brain tissue, or lead to permanent alterations of serotonergic neuron function, rather 
than promoting complete cell death.  
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Cannabis 
 
History and Use 
 
The term cannabis describes the natural hemp plant (cannabis sativa/indica) and its products and 
derivatives, which have a long history of ritual, medicinal, industrial and recreational use. Native to 
central Asia, earliest narratives of use have been dated back to 3000 B.C. In the 18th century, 
cannabis plants and first descriptions of its medical and psychoactive potential appeared in 
Europe. In 1839, a comprehensive description of the medical uses of Indian hemp (cannabis 
indica) by an Irish doctor stationed in Calcutta sparked its use for medical purposes around Europe 
(see Excursion 3: Medical use of cannabis) (Murray et al., 2007). By the mid-20th century, 
chemical substances (for example, aspirin) replaced cannabis as promising pharmaceutical agent. 
Furthermore, its instable effects, and increasing legal restrictions lead to a decline of medical use 
of cannabis products (Aldrich, 1997). Today, it is almost exclusively used for recreational purposes. 
In fact, cannabis is the most consumed illegal psychoactive substance world wide. It is third in line 
of the most commonly (ab)used drugs, following the legal substances alcohol and nicotine 
(EMCDDA, 2008). Most common cannabis products for recreational use are marihuana (from the 
dried leaves and buds) and hashish (from the concentrated resin) (Fig.6).  
                                                                                          
 
 
 
 
 
 
Fig.6: Cannabis leaves of cannabis sativa (left) and hashish blocks (right). Of the three different 
varieties of the plant, today cannabis sativa is the most frequently grown. Marihuana is produced from the 
dried leaves and flowering tops, whereas hashish is made of the resin of the plant. (retrieved  from 
www.wissen.dradio.de and www.freedrugzone.com) 
 
 
The cannabis plant contains at least 60 active cannabinoids, of which delta9-Tetrahydrocannabinol 
(∆9-THC, THC) is the primary psychoactive constituent and cannabidiol the major sedative 
compound. The major cannabinoids found in the female plant are inactive carboxyl acids, which 
are transformed into active phenols by heating (smoking, baking). THC is readily absorbed by 
inhalation and evident in the plasma within seconds. It is estimated that maximal concentration of 
THC (approx. 1 %) is reached in the brain 15 minutes after inhalation (Grotenhermen, 1999). 
Subsequently, THC exerts its actions by binding to endogenous cannabinoid receptors, while 
mechanisms underlying the effects of cannabidiol are not clearly established (although its binding 
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to a G-protein-coupled receptor, GPR555, is confirmed) (Howlett et al., 2002). The concentrations 
and ratios of THC, cannabidiol and other cannabinoids, and thus the effects of the drug, vary 
greatly according to plant breeding, cultivation, post-harvesting techniques and countries. The 
potency of cannabinoid drugs is usually expressed in terms of THC content. Seizured cannabis 
products in the EU contained between 1 and 15% of THC. Generally, the THC content is higher in 
hashish than in marihuana (EMCDDA, 2010).  
Since cannabinoids (including THC) are lipophilic, they accumulate in fatty tissue of the body and 
are metabolized and secreted slowly. Therefore, THC metabolites (some of which retain 
pharmacological activity) can be detected up to seven days after consumption in blood samples, 
and up to two weeks in urine. Interestingly, some of the hepatic enzymes responsible for 
metabolism of THC are inhibited by canabidiol (Ashton, 2001). 
 
Cannabis is able to grow in many environments, thus trafficking routes for marihuana are generally 
regional and cultivation mainly occurs indoors (e.g., within Europe). On the other hand, reports 
from the United Nations (UN) suggest Afghanistan and Morocco to be the biggest suppliers of 
hashish, grown on outdoor cultivation plants. The UN world drug report estimates the global 
production of cannabis products for the year 2008 between 13 000 and 66 000 tons (UNODC, 
2010). 
 
In most countries cultivation, possession, and distribution of cannabis is illegal. However, some 
states in the USA and also Europe (including Germany, Italy, Portugal) decriminalize possession of 
small amounts, such that punishment involves a fine rather than more severe penalties.  
 
Special case- The Netherlands: In the Netherlands, the decriminalization of cannabis in 1976, and 
subsequent legalization of cannabis sales in “coffee shops” meeting certain set criteria (but not the 
possession, distribution or use elsewhere) has been ground for debate. However, when comparing 
cannabis use data from the Netherlands to other European countries, similar trends are observed 
regardless of the legal status of the drug. In the mid-90s, local communities received the 
opportunity to decide whether they want coffee shops or not. Since then, many coffee shops have 
been closed and today are mainly restricted to the large communities (EMCDDA, 2008). Recently, 
new legal arrangements have been put forward, including restricting cannabis use to registered 
members, and allowing a maximal amount of 15% THC in cannabis products sold in coffee shops.  
 
Prevalence  
 
Most people have tried some form of cannabis at some point in their life. First experimental contact 
usually occurs during adolescence or young adulthood. Some people become regular users, and 
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of these, a minority (10%) becomes heavy (i.e., daily) consumers. The majority of consumers stops 
around age 30 or older. The world drug report of the UN states the 12 months prevalence among 
adults (15-64 year olds) between 2.8 and 4.5%, depending on the country (Fig.7). This estimate is 
lower than figures from the European and German drug monitoring centres, indicating that 6.7% of 
European and 9.7% of German adults have used cannabis during the last year. Numbers are 
higher for young adults (European 15-24 year olds: 15.2%) as well as adolescents, and for males 
compared to females (EMCDDA, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7: Cannabis consumption and main cultivation areas world wide. 12-months prevalence rates from 
2009 or latest data available (UNODC, 2010). Consumption over the last 20 years has risen but recent data 
suggest it is currently stable in most European countries.  
 
Effects 
 
Acute (and desired) psychological effects upon cannabis consumption include mild euphoria and 
relaxation, heightened sensory perception, and increased sociability (Hall and Degenhardt, 2009). 
Physiologically, cannabinoids stimulate appetite and have antinociceptive as well as sedative 
properties. Additionally, impairments in short-term and working memory, attention, decision 
making, and distortions in time and space perception appear (Iversen, 2003). In terms of motor 
behaviour, increased motor activity may be followed by incoordination, weakness, and ataxia 
(Kumar et al., 2001). Adverse effects like panic attacks and anxiety (mainly in novel users) as well 
as increased heart rate, lowered blood pressure and dry mouth have been reported. Furthermore, 
high doses can lead to psychotic symptoms (Chopra and Smith, 1974; D'Souza et al., 2004). 
Results from experimental studies in animals show similar effects of THC. For example, dose-
dependent modulation of locomotor activity, food intake, pain, body temperature and memory was 
demonstrated (Ameri, 1999). More specifically, experiments in rats indicate a cannabinoid-
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mediated dysfunction of the hippocampus, the brain area closely involved in learning and memory. 
In hippocampal cell cultures, cannabinoid agonists decreased long-term potentiation (LTP), a 
molecular mechanism crucial for short-term memory and storage of information (Schlicker and 
Kathmann, 2001; Sullivan, 2000).  
Risks, long-term effects & impairments 
 
There are no reports of deaths caused directly by cannabis consumption; the risk of an overdose is 
close to zero. However, traffic accidents involving cannabis have been reported: acute cannabis 
consumption increases the risk of motor vehicle crashes, probably due to impaired time perception, 
attention and slowed reaction times  (Asbridge et al., 2012; Ameri, 1999). 
Cannabis can lead to psychological habituation and dependence as defined by the international 
classification for mental disorders (DSM IV) in about 10% of regular users. Development of 
tolerance, i.e. the need for an increased dose to produce the same effect, is common in cannabis 
users, and rewarding properties of THC have been confirmed in self-administration experiments in 
animals (Iversen, 2003; Tanda and Goldberg, 2003). Withdrawal symptoms, including negative 
mood (anxiety, depression, irritability), sleep disturbance and decreased appetite have been 
reported by regular users who stop consumption, and replicated in animal models (Ameri, 1999).  
Long-time cognitive deficits are debated. Several studies found no correlation between heavy 
cannabis use and IQ or cognitive deficits after 28 days of abstinence (Pope et al., 2002), while 
others found persistent dose- or onset-related impairments of memory, learning, attention and 
decision making in a gambling task (Solowij and Battisti, 2008; Bolla et al., 2005). Neuroimaging 
studies demonstrate changes in brain structures related to these cognitive functions. For example, 
diminished activity in prefrontal cortex, hippocampus and cerebellum have been found in heavy 
cannabis consumers (Block et al., 2002; Nestor et al., 2008). Alterations of cannbinoid binding to 
its receptor in the brain have also been found (Howlett et al., 2004), suggesting changes on a 
cellular level in response to chronic administration of cannabinoid agents. 
Consumption of cannabis has been associated with an increased risk for psychiatric conditions, 
namely schizophrenia (Arseneault et al., 2004) and depression (Degenhardt et al., 2003). This is 
especially true for adolescent individuals and those with a preexisting vulnerability to psychiatric 
conditions. Although many retrospective studies suffer from the drawback of incomplete control 
groups and inadequate possibilities to control for confounding factors such as personality, well-
designed longitudinal studies indicate that cannabis use is a risk factor for incident psychotic 
symptoms, and its continued use can contribute to the persistence of the symptoms or 
development of a psychotic disorder (Kuepper et al., 2011). In schizophrenic patients, cannabis 
use can exacerbate symptoms and increase the frequency of relapses (Kumar et al., 2001). 
Furthermore, an association between cannabis use and polymorphism in the gene encoding 
catechol-O-methyltransferase (COMT) was found in current patients (Costas et al., 2011) and 
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cannabis using adolescents who later developed psychosis (Caspi et al., 2005). In line with this, 
COMT variation was found to modulate THC-induced psychotic experiences as well as 
impairments in cognition (attention and memory) (Henquet et al., 2006).  
In animal models, similar effects were found after administration of synthetic cannabinoid drugs. 
Rats treated chronically during puberty with a cannabinoid receptor agonist showed more severe 
and persistent deficits in short-term memory information processing and in social tasks compared 
to those animals treated during adulthood (Schneider et al., 2008). Furthermore, a deficit in 
sensorimotor gating mechanisms, a phenomenon which has been observed in neuropsychiatric 
disorders like schizophrenia, together with alterations in gene expression in certain parts of the 
brain was evident after chronic pubertal treatment (Wegener and Koch, 2009b).  
The probability for persistence of the above mentioned impairments rises with increased frequency 
and dose of use, as well as with initiation of cannabis consumption during puberty. Occasional use, 
especially during adulthood, is associated with relatively low risks (Iversen, 2005). 
The most robust associations were found between cannabis use and reduced educational 
achievement as well as increased used of other drugs, and health problems involving the 
respiratory system, for example, chronic bronchitis (Macleod et al., 2004). Risk of developing 
pharyngeal or lung cancer is increased in cannabis smokers. However, many studies caution that 
most of their subjects also smoke tobacco (Hall, 1998). 
 
Excursion 3: Medical use of cannabis 
For millennia, cannabis has been known for its medicinal properties. In 1839, a comprehensive description of 
the medical uses of Indian hemp (cannabis indica) by the Irish doctor O’Shaughnessy stationed in Calcutta 
sparked its use for medical purposes around Europe. Shortly afterwards, French psychiatrists discovered the 
potential of hashish to treat psychiatric conditions, and describe their physical and psychological effects. 
Between 1880 and 1900, the medical use of hashish had become widespread in Europe and the USA, and 
the main pharmaceutical companies manufactured cannabis products. Most important applications were 
against pain, migraine, asthma and insomnia, followed by symptoms of cholera. Rarely it was used to treat 
depression and diminished appetite (Aldrich, 1997).  
The discovery of endogenous cannabinoid receptors and their ligands as well as the development of 
synthetic ligands in the late 20th century has further specified the medically relevant properties of 
cannabinoids. These include anti-emetic (preventing nausea and vomiting), analgesic (reducing acute and 
inflammatory pain), and orexigenic (increasing appetite and food intake) effects. Anecdotal reports from 
patients suffering from multiple sclerosis suggested reductions in pain and spasticity following cannabis 
consumption (Consroe et al., 1997). Recent experimental studies employing animal models of multiple 
sclerosis and pain confirmed these reports, as mice showed less tremors and spasms following 
administration of cannabinoids (Baker et al., 2003), and rats had diminished pain reaction in response to 
neuropathic and chronic pain after treatment with a cannabinoid receptor agonist (Kumar et al., 2001). On a  
cellular level, THC and cannabidiol have anti-inflammatory and anti-oxidant properties (Hampson et al., 
1998). 
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Examples of implementation 
Although cannabis is a scheduled drug according to USA federal government laws, 15 states have passed a 
law in 1996 which allows possession of a small amount of cannabis for medical purposes. Patients, mostly 
suffering from diseases involving chronic pain, extreme loss of body weight or chemotherapy, need written 
referral of a medical practitioner and obtain their share from so called “caregivers”, who legally cultivate 
cannabis plants for these restricted purposes. Local authorities are officially asked to de-prioritize 
persecution of consumers and suppliers of medicinal cannabis. In the Netherlands, cannabis can be bought 
in pharmacies with a prescription since 2003. Many other European countries consider altering their laws to 
permit cannabis use for medical purposes, depending on outstanding results of large scale clinical trials and 
scientifically sound research. 
 
Neuroprotective properties 
Substantial experimental evidence indicates neuroprotective properties of cannabinoids. In vivo 
administration of synthetic cannabinoid agonists (e.g., WIN55,212-2), THC, cannbidiol or endocannabinoids 
such as anandamide protected against global and local ischemic damage and poison-induced excitotoxicity. 
Studies in cultured cells have supported these findings, as the cannabinoid agonist CP55,940 protected 
cortical neurons from glutamatergic excitotoxicity (Sarne and Keren, 2004; Sarne and Mechoulam, 2005). 
These neuroprotective effects of cannabinoids have been attributed to the modulation of calcium-dependent 
mechanisms which play a role in neuronal damage and cell death. Thereby, cannabinoids directly (reducing 
free radical production) and indirectly (reducing glutamate release and subsequent excitotoxicity as well as 
nitric oxide synthesis) decrease cell death by attenuating intracellular calcium (Grundy et al., 2001). 
Nevertheless, low doses or concentrations of cannabinoids and THC given over a long period of time do 
have neurotoxic properties. This is of special importance when considering medical use of cannabinoid 
agents. 
 
Current developments 
Extensive research into the beneficial properties of cannabinoid ligands without psychoactive side-effects 
has been undertaken by pharmaceutical industries and independent sources. Apart from the above 
mentioned effects, research examines the therapeutic potential against cancer and auto-immune diseases 
and addiction. For example, two synthetic cannabinoid receptor agonists, dronabinol and nabilone, have 
already been approved for medical use since the 1980s (Manzo, 1988). Recently, sativex, a cannabis plant 
extract which is delivered as an oral spray, has been developed and approved for treatment of pain in 
patients with multiple sclerosis in Canada (Novotna et al., 2011). A second new drug is the cannabinoid 
receptor antagonist rimonabant, which has been developed to treat obesity and received recommendations 
for approval in the EU. However, high drop-out rates in the clinical trials and many side effects, for example 
depression, lead the USA to reject the drug (Christensen et al., 2007). Further cannabis-related drugs for 
various medical conditions are currently under research. Substances inhibiting endocannabinoid 
degradation, or new synthetic analogues which lack psychoactive side effects or exert their effects on the 
allosteric site of the cannbinoid receptor in the brain could prove valuable as adjunct therapeutics.  
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Pharmacology  
 
Endocannabinoid system 
 
Considering the long history of cannabis use, chemical isolation and identification of the 
psychoactive ingredients of the plant (Mechoulam and Gaoni, 1967), followed by the discovery of 
endogenous cannabinoid receptors and identification of endogenous substances acting on these 
receptors occurred fairly recently. The term “endocannabinoid system” includes at least two 
specific cannabinoid receptor types, the cannabinoid receptor1 (CB1, discovered 1988 (Devane et 
al., 1988)) and cannabinoid receptor2 (CB2, discovered 1992 (Munro et al., 1993)), as well as their 
endogenous ligands. CB1 is primarily found in the central and peripheral nervous system (CNS 
and PNS), whereas CB2 is mainly located in the periphery, specifically in tissues of the immune 
system. The most extensively researched endocannabinoids are anandaminde and 2-
arachidonylglycerol  (2-AG) (Piomelli, 2003). Since the discovery of the endocannabinoid system, 
research has determined its involvement in the modulation of analgesia, cognition, memory, 
locomotor activity, appetite stimuli, food intake and reward properties of drugs and immune control. 
The endocannabinoid system regulates synaptic neurotransmission by influencing the release of 
neurotransmitters. Postsynaptically synthesized and released endocannabinoids act as retrograde 
messangers to presynaptic CB receptors, which they activate tonically (Howlett et al., 2004). In 
response to a depolarization of the postsynapse, endocannabinoids increasingly stimulate CB1 
receptors, which leads to inhibition of neurotransmitter release (see Fig.8B). Action of 
endocannabinoids at the CB1 receptor is terminated by a carrier-mediated mechanism and 
subsequent enzymatic action of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (in 
case of 2-AG) (Wegener and Koch, 2009a). 
 
Synthetic cannabinoid receptor ligands, for example CB1 agonists WIN55,212-2 (WIN), CP55,940, 
and CB1 antagonists AM251 and SR141716A (Rimonabant), have been developed to increase the 
understanding of the endocannabinoid system as well as to investigate the mechanisms by which 
exogenous cannbinoids (e.g., THC) exert their effects on a variety of physiological and 
psychological processes.  
 
CB1 receptor 
 
The CB1 is a presynaptically located Gi-protein coupled receptor which is widely distributed 
throughout the brain. It has also been discovered in peripheral sympathetic neurons as well as in 
cells of the immune system, the spleen, and testes (Pertwee et al., 2010). In the CNS, both endo-
and exogenous cannabinoids act as retrograde messengers on CB1, thereby inhibiting the release 
of neurotransmitters (Wilson and Nicoll, 2002) (see Fig.8B). CB1 is predominantly found on 
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terminals of inhibitory gamma-aminobytric acid (GABA)-ergic interneurons and glutamatergic 
neurons, especially in the cortex, cerebellum and hippocampus. Other neurotransmitters affected 
are noradrenaline, DA, 5-HT and acetylcholine (Kano et al., 2009; Kawamura et al., 2006; Tsou et 
al., 1998). On DA and 5-HT neurons, CB1 is additionally expressed on extrasynaptic axonal and 
somatodendritic sites (Lau and Schloss, 2008). The CB1 forms functional heteromers with other 
receptors, including DA D2 receptors in the hippocampus and cortex and opiod µ receptors in the 
spinal cord (Pertwee et al., 2010). Endocannabinoids are involved in depolarization-induced 
suppression of inhibition (in the hippocampus) and excitation (in the cerebellum) in response to 
local signal transmission on particular neurons. On the other hand, exogenous cannbinoids reduce 
neurotransmission on a larger scale due to activation of CB1 all over the brain (Wilson and Nicoll, 
2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8: A) Distribution of the CB1 throughout the rat brain B) simplified schematic diagram of the 
presynaptic mechanisms influencing signal transduction A) Photograph of a sagittal brain slice from an 
early study using the radioligand [H3]CP55,940, which binds with high affinity to the CB1 (adapted from 
Herkenham, 1990). Highest densities were found in the frontal cerebral cortex, anterior cingulated cortex 
(Cx), thalamus (Th), basal ganglia (CP, caudate putamen, GP, globus pallidus, SNr, substantia nigra), 
hippocampus (Hi), cerebellum (Cer) and olfactory bulb as well as spinal cord (Herkenham et al., 1990). This 
heterogenous pattern of distribution accounts for the effects of cannabinoid substances on cognition, 
memory and learning, movement control and coordination, as well as pain perception. Low density in the 
brainstem (BrSt), which controls many autonomic functions, probably accounts for the lack of cannabis-
induced fatalities. More recent neuroimaging studies in humans and rats have supported this distribution, as 
the pattern of functional activation matched the behavioural profile (Howlett et al., 2004). B) Two main 
mechanisms by which endocannabinoids and CB1 agonists inhibit neurotransmitter release: 1) activation of 
K+ (A-type and inwardly rectifying) channels leads to an increased potassium efflux, reducing the 
presynapitc action potential and thus neurotransmitter release. This occurs by a) direct G-protein-mediated 
activation, and b) inhibition of adenylate cyclase activity, leading to a decrease of cAMP in the synapse and 
subsequent reduction of protein kinase-mediated phosphorylation of K+ channels. 2) G-protein-mediated 
inhibition of voltage-dependent N and P/Q-type Ca2+ channels, thereby reducing intracellular Ca2+ 
concentration which is necessary for neurotransmitter release. Furthermore, activation of the CB1 stimulates 
mitogen-activated protein (MAP) kinase pathways (Schlicker and Kathmann, 2001; Ameri, 1999). 
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Decision making 
 
Individuals are faced with an ever-changing environment in which making choices is a crucial 
process for adaptation and associative learning in everyday life. Decision making can be defined 
as the cognitive process during which two or more alternatives are compared, resulting in a choice 
for a (behavioural) action. Decision making is a complex cognitive but mostly automatic process 
which involves various steps. When faced with a choice of different behavioural options, 
characteristics of the benefit or reward of each action are weighed against the (expected or known) 
costs to reach the optimal solution. Subsequently, the choice is transformed into a response and a 
reaction is executed. Decisions, conscious or unconscious, are cost-benefit evaluations. 
 
Deficits in decision making have been shown in patients with focal lesions of the involved brain 
regions, and in individuals with psychiatric disorders, for example, schizophrenia, depression and 
drug addiction, who tend to choose a cost-aversive alternative, or repeat maladaptive choices 
despite knowing the adverse consequences (Bechara et al., 2000; Grant et al., 2000). 
 
Two different, yet interrelated forms of cost-benefit decision making are delay-based and effort-
based choice. Delay-based tasks test the ability to tolerate delays before a reward (i.e., how long 
an individual is willing to wait before receiving a large reward), and have been implemented as 
animal models of impulsive choice. Effort-based tasks measure how much physical work is 
invested for a large reward. In animal models differentiating between these forms of decision 
making, the different costs are manipulated. Delay-based paradigms usually employ 10-15 
seconds of waiting time for the higher reward. Effort-based tasks increase the amount of physical 
work, either by increasing the number of lever presses or by inserting a barrier which the animal 
has to climb in order to obtain the large reward (Fig.9).  
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Fig.9: Schematic diagram of a) delay- and b) effort-based experimental tasks in a T-maze. Rats are 
placed in the start arm and choose between a high cost option (waiting time between gate A and gate B or 
effortful climbing of a barrier) to obtain a large reward, and a low-cost option (no delay, no barrier) to obtain a 
small reward. Under normal circumstances, rats trained on these tasks decide in favor of the large reward 
over the small reward even if its attainment is associated with a delay or effort. LRA=low reward arm, 
HRA=high reward arm (adapted from Rudebeck, 2006). 
 
In line with human studies, (pre)frontal cortex regions including the anterior cingulated cortex 
(ACC) and the orbitofrontal cortex (OFC), but also the basolateral amygdala (BLA) as well as the 
nucleus accumbens (NAC) have been associated with decision making in animal models. In 
addition, memory-based, and motor controlled aspects of choice behaviour require recruitment of 
the hippocampus and cerebellum (Ernst et al., 2002). Furthermore, distinct forms of cost-benefit 
choices seem to depend on different frontal regions. In a human study, options involving increasing 
effort- or delay-based costs were discounted in the same behavioural manner, however processing 
in the brain could be dissociated for effort (ACC) and delay (medial PFC) devaluation (Prevost et 
al., 2010). Lesions of the OFC of rats led to a decrease in choices for a large reward if the cost was 
a delay. On the other hand, lesions of the ACC led to decreased choices for the large reward if the 
cost was effort (Walton et al., 2003; Floresco and Ghods-Sharifi, 2007). However, either brain 
region is solely involved in decision processes. Rather, they are part of a neural network, as “both 
ACC and OFC send afferent projections to the nucleus accumbens, albeit to distinct subregions, 
[and to the BLA] suggesting there may be distinct fronto-striatal loops which process effort and 
delay costs”  (Rudebeck et al., 2006)(p.1166). In fact, disruption of the connection between ACC 
and the BLA decreased HRA choices in an effort-based T-maze task (Floresco and Ghods-Sharifi, 
2007), and inactivation of the NAC core, but not shell subregion, reduced the choices for the high 
reward arm in effort- as well as delay-based tasks (Ghods-Sharifi and Floresco, 2010; Cardinal et 
al., 2001). Thus, these interconnected subcortical regions (representing a “limbic-motor interface” 
and the emotional/motivational value (Mogenson et al., 1980; Homberg, 2012)) play a crucial role 
in cost-benefit decision making, whereas frontal cortical brain regions differentiate between the 
different forms of costs.  
 
Furthermore, dissociable neurochemical mechanisms involving monoamine transmitters mediate 
effort- and delay-based decisions. 5-HT modulates delay-based choices, as reduction of 5-HT 
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functioning leads to more impulsive behaviour in humans and animals (Cardinal, 2006). Moreover, 
5-HT synthesis blocker increase the choices for the LRA. This effect may be reversed after chronic 
treatment with serotonergic drugs (Liu et al., 2004). On the other hand, the DA system is involved 
in delay- as well as effort-based decisions (Denk et al., 2005). Specifically, D1 and D2 receptor 
antagonists shift rats choices towards the small reward option (Bardgett et al., 2009).  
Influence of MDMA 
 
Retrospective studies in human MDMA users point to deficits in cognitive functions including 
memory, attention, and decision making. 
 
MDMA is perceived as a “serotonergic drug”, as its major behavioural and physiological effects are 
mediated by the influence on 5-HT activity, followed by DA and NA. On cortico-limbic structures, 5-
HT neurons and receptors are present abundantly, thus the 5-HT system seems closely involved in 
cognitive processes (Homberg, 2012). 
 
As mentioned above, delay-based decisions have been shown to be under control of 5-HT 
transmission (Denk et al., 2005). Specifically, increases in 5-HT activation (for example, by 
selective serotonin reuptake inhibitors, SSRIs) enables longer waiting, whereas reduced 5-HT 
levels lead to impulsive choices (Homberg, 2012). While MDMA causes an acute increase of 
extracellular 5-HT (and DA and NA) levels, chronic stimulation of the 5-HT system leads to a 
reduction of 5-HT synthesis via inhibition of tryptophan hydroxylase (Green et al., 2003). In line 
with this, SERT-deficient rats showed improved inhibitory control (Homberg et al., 2007), and 
studies investigating decision making and impulsive behaviour in drug users demonstrate 
increased impulsive choice as well as deficits in decision making in heavy, long-term MDMA users 
(Quednow et al., 2007; Morgan et al., 2006). A replicated finding from neuroimaging studies are 
reduced SERT levels in abstinent MDMA users (Cowan, 2007). However, the degree and time 
span of MDMA-induced serotonergic dysfunction in prefrontal or OFC regions remains 
inconclusive. On the other hand, studies investigating drug users reporting weak or moderate 
MDMA consumption found that drug use per se, rather than MDMA exclusively, contributes to 
impairments in decision making (Hanson et al., 2008), or did not find fundamental differences 
compared to control groups (Halpern et al., 2011). In line with this, binge administration of MDMA 
to rats acutely decreased inhibitory control, however the behavioural effect was not evident seven 
days later despite decreases in frontal cortex 5-HT levels (Saadat et al., 2006). Acute and chronic 
effects of MDMA on effort-based decision making remain to be investigated.  
The long-term effects of MDMA on decision making seem to depend on (life time) dosage, as 
heavier and chronic use is associated with more severe deficits, probably attributable to functional 
alterations in the brain.  
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Influence of Cannabis 
 
Most research examining the influence of cannabis on cognitive functions focuses, and agrees on, 
(short term) memory impairments following acute consumption (Morgan et al., 2010), whereas 
persistent memory impairment due to chronic consumption is less established (Solowij and Battisti, 
2008). 
 
In contrast to memory, cognitive processes such as decision making have only been examined 
scarcely. In one study employing a gambling task, the authors conclude that “[cannabis] users 
made more decisions that led to larger immediate gains despite more costly losses than controls” 
(Whitlow et al., 2004)(p.107). A recent study combining a gambling task with imaging technique 
found that heavy cannabis users (who were abstinent for 25 days prior to testing in order to 
exclude confounders such as remaining drug derivatives and withdrawal symptoms) showed 
maladaptive decision making coupled with decreased brain activity in the OFC (Bolla et al., 2005). 
However, one study found no effects of acute consumption of THC (McDonald et al., 2003), and 
other studies found no difference in decision making between current cannabis users and controls 
tasks (Quednow et al., 2007) or following 28 days of controlled abstinence (Pope et al., 2002). 
 
In animal experiments, a complex role of the cannabinoid system in decision making was shown. 
In a delay-based paradigm, CB1 receptor antagonists improved inhibitory control or blocked the 
amphetamine-induced increase of impulsive choice, but administration of CB1 agonists also 
decreased impulsive choice (THC) or had no effect on delay-based choices (WIN55,212-2) 
(Wiskerke et al., 2011; Pattij et al., 2007). Since activation of the CB1 receptor exerts inhibitory 
control over the DA as well as 5-HT system, both implicated in decision making, modulation of the 
endocannabinoid tone or selective CB1 activation in OFC or ACC should improve knowledge about 
the influence of the cannabinoid system on decision making. 
 
These results point to an association between MDMA and possibly also cannabis consumption and 
deficits in decision making; however, as immanent in retrospective human studies predisposition to 
maladaptive choices or impulsivity (two risk factors for drug abuse), as well as pre-existing brain 
dysfunction cannot be ruled out.  
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MDMA & Cannabis 
 
Any study involving human ecstasy users inevitably faces difficulties in interpreting the results due 
to (the possibility of) polydrug use. This may be caused by impurity of ecstasy tablets, containing a 
variety of other psychoactive substances and/or stimulants, making attribution of effects to MDMA 
use difficult. Furthermore, polydrug use, especially among young adults, has become normality 
rather than rarity (EMCDDA, 2009). Specifically, MDMA use has been associated with elevated 
consumption of legal drugs including alcohol, cigarettes, and illegal drugs, for example cannabis as 
well as other psychostimulants such as amphetamine, meta-amphetamine, and cocaine (Grov et 
al., 2009). Cannabis is by far the most common concomitantly taken illegal substance to MDMA 
(Gouzoulis-Mayfrank and Daumann, 2006b). These two drugs differ markedly in their biological 
effects. However, research examining neurobiological, behavioural and cognitive effects of co-
consumption in humans or animal models is scarce (see Review). 
 
 
MDMA Cannabis 
Facts 
Origin 
Synthetic 
amphetamine 
derivative 
Natural hemp plant: 
cannabis 
indica/sativa 
First appearance 1912 3000 b.c. 
Major form of intake Oral (pills) Inhaled (smoked) 
Duration of effect 3-5 hours 1-3 hours 
Half life (human) Approx. 8-11 hours Up to 55 hours 
Metabolism 
Hepatic,  
CYP2D enzyme 
Hepatic,  
CYP enzymes 
Neurochemical 
mechanism 
Reuptake 
inhibitor/releaser of  
5-HT, DA, and NE 
Agonist on CB1 
and CB2 receptors 
LD50 
97mg/kg i.p. (mice), 
49mg/kg i.p. (rats) 
660mg/kg oral 
(rats) 
Effects 
  
temperature hyperthermic hypothermic 
oxidative stress increasing decreasing  
activity increasing decreasing 
food intake/appetite hypophagia hyperphagia 
subjective effect stimulant relaxant , stimulant  
 
 
                               Table 1: Comparison of facts and effects of MDMA and cannabis. 
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Aim of the thesis and summaries 
 
The thesis aims to increase the understanding of changes in cognitive and behavioural functioning 
following acute or chronic administration of 3,4-methylenedioxymethamphetamine (MDMA, 
“ecstasy”). Specifically, animal models of decision making and memory are implemented. The 
influence of the cannabinoid receptor agonist WIN55,212-2 as well as interactive effects between 
MDMA and CB1 receptor stimulation on these measures are studied in adult and pubertal rats. 
Following chronic treatment, histological examination of the myelination levels in various brain 
areas is carried out. 
 
Review 
 
In “MDMA & Cannabis: A Mini-Review of Cognitive, Behavioral, and Neurobiological Effects of Co-
consumption” I reviewed recent studies investigating the combination of MDMA and cannabis or 
cannabinoid agents on cognitive functions, behavior, and neurobiological interactions. Human 
studies examining the effect of concomitant use on cognitive functions reveal inconsistent results. 
Some demonstrate cannabis-induced impairments of memory, and learning and decision making 
deficits attributable to MDMA use only. Others show that polydrug use leads to additive negative 
effects. However, different inclusion criteria (heaviness of life time MDMA use, time of abstinence, 
co-consumption of other drugs) and control groups (including or excluding cannabis use, abstinent 
or naïve MDMA user) make conclusive comparisons difficult. Furthermore, although most studies 
investigating polydrug users are retrospective, there is a shortage of animal studies modeling 
chronic co-use and its consequences.  In acute animal models, the cannbinoid system has been 
shown to regulate the reinforcing effects of MDMA. Furthermore, disruption of working memory as 
well as abolishment of deficits in an object recognition task was evident with co-administration. 
These results point to an interaction of MDMA-induced alterations of neurotransmission, 
specifically the 5-HT system, and cannabinoid receptor activation in the hippocampus. 
Furthermore, cannabinoid agents were shown to have a modulating effect on MDMA-induced 
changes in body temperature and locomotion in animal models, and presumed neurotoxicity in cell 
cultures. 
 
Study 1 
 
“Acute Co-administration of the Cannabinoid Receptor Agonist WIN55-212,2 does not influence 
3,4-methylenedioxymetamphetamine (MDMA)-induced Effects on Effort-based Decision making, 
Locomotion, Food intake and Body temperature“ investigates possible interactions of MDMA 
(7.5mg/kg, s.c.) and WIN (1.2mg/kg, i.p.) on various behavioural tasks when administered alone 
Aim of the thesis and summaries
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and in combination. As a measure for cognitive ability, effort-based decision making was tested in 
a T-maze paradigm. MDMA as well as MDMA-WIN administration induced effort-aversive choice, 
whereas WIN alone had no effect. Furthermore, MDMA as well as MDMA+WIN decreased food 
intake and increased locomotor and exploratory behaviour, whereas effects of WIN did not differ 
from control. The only (tentative) interaction was seen within the open filed: MDMA induced 
anxiety-like behaviour, which was diminished by co-administration of WIN. The underlying 
neurobiological alterations remain speculative. However, our data indicate that effects of acute 
MDMA not only include the established physiological responses like hyperthermia and increased 
activity, but may also immediately impair cognitive functions like decision making. Generally, co-
administration of WIN did not have modulatory effects on behavioural changes induced by acute 
MDMA administration. 
 
Study 2 
 
“Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or 
adulthood reverses 3,4-methylenedioxymetamphetamine (MDMA)-induced deficits in recognition 
memory but not in effort-based decision making“ deals with the effects of chronic administration of 
either MDMA (7.5mg/kg, s.c.) or WIN (1.2mg/kg, i.p.) alone or in combination, to either adult 
(postnatal day (PD) >80) or pubertal (PD 40-65) animals. After 25 days of irregular treatment, all 
MDMA-treated animals showed a significant deficit in short-term memory (tested with the object 
recognition task), which was not evident when WIN was co-administered. This deficit persisted in 
pubertally treated animals when re-tested four weeks later. MDMA and MDMA+WIN-treated adult 
animals showed problems in effort-based decision making, as they took longer to re-learn the task 
in comparison to vehicle or WIN-treated animals, whereas there were no apparent differences 
between the pubertally treated groups. No effects of chronic treatment were apparent for the delay-
based task. Furthermore, there were no differences between the four treatment groups of both 
ages in terms of horizontal locomotor activity or exploratory behaviour shortly after cessation of 
treatment or four weeks later. WIN had no modulator effect on MDMA-induced decrease in weight 
change of the pubertal rats during treatment. In conclusion, regardless of treatment age, chronic 
CB1 receptor stimulation is capable of modulating long-term MDMA-induced deficits in basic 
memory performance, presumably due to altered (serotonergic) neurotransmission. This 
interaction is most likely localized to the hippocampus, whereas no amelioration of MDMA-induced 
disruption seems to take place in prefrontal areas responsible for more complex tasks like effort-
based decision in rats treated during adulthood. 
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MDMA & Cannabis: A Mini-Review of Cognitive, Behavioral, and Neurobiological 
Effects of Co-consumption 
 
Sybille Schulz 
 
Abstract 
 
 Although the prevalence of co-use of cannabis and 3,4-methylenedioxymethamphetamine 
(MDMA) is very common among polydrug users in western societies, few studies have tested the 
consequences on behavior, cognition or neurobiology. This review examines 23 articles published 
between 2002 and 2010 with an explicit focus on the combination, or administration, of MDMA and 
cannabis or cannabinoid agents. The aim was to provide a short overview on the latest human 
research concerning cognitive effects of co-consumption of MDMA and cannabis, and a more 
elaborate picture of the state of knowledge about the interaction of cannabinoid agents and MDMA 
from animal studies. It was found that recent retrospective studies on cognitive functions in long-
term drug abusers point to an additive negative effect on different types of memory, as well as a 
cannabis-independent decrease in learning and decision making in MDMA users. Behavioral 
experiments in rodents and in vitro studies investigating the combined effect of MDMA and 
cannabinoid agents demonstrate modulator effects of acute co-administration on measures like 
body temperature, conditioned reinforcement, and presumed neurotoxicity. As neural mechanism 
underlying these changes, an interaction between the cannabinoid system, especially cannabinoid 
receptor 1, and the serotonergic and dopaminergic system in the prefrontal cortex, nucleus 
accumbens, and hippocampus is suggested. In conclusion, there are few and somewhat 
contradictory studies examining the effects of co-use of these drugs on cognitive measures like 
impulsivity, memory and executive functions or underlying neurobiological alterations, and a 
shortage of animal studies examining long-term effects of chronic co-administration. 
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Introduction  
 
Not only did the consumption of illicit drugs like cannabis, MDMA (3,4-
methylenedioxymethamphetamine, “ecstasy”) or other psychotropic substances increase during 
the last decade, but particularly polydrug use among young people has augmented concerns about 
aversive effects and increased challenges in drug abuse research investigating the effects of any 
specific drug (Scholey et al., 2004; EMCDDA, 2010). For instance, reports of recreational MDMA 
users disclose a strong abuse of a range of other psychoactive compounds and drugs (Braida et 
al., 2005). In fact, 98% of MDMA users have used cannabis at some point in their life (although not 
all cannabis consumers become regular MDMA users) (Fox et al., 2001; Gouzoulis-Mayfrank and 
Daumann, 2006b). More specifically, cannabis is revealed to be the most widely taken illegal co-
drug in MDMA users, especially among younger adults. Ninety to ninety-eight per cent report to 
concomitantly have smoked cannabis (e.g., USA: 98%, lifetime prevalence (Keyes et al., 2008; Wu 
et al., 2009; Grov et al., 2009); UK: 89%, 12-month-prevalence (Smith et al., 2011)), and many of 
them consume both drugs at the same time (Parrott et al., 2004). The decision for polydrug use 
might be influenced by psychological and functional aspects (Parrott et al., 2004; Degenhardt et 
al., 2001). In contrast to the initial entactogenic and euphoric effects upon acute administration, 
decreasing concentrations of MDMA in the brain can lead to anxiety, agitation, insomnia and 
depressive feelings. Due to its sedative properties, cannabis might be taken as remedy to relieve 
these negative physiological and emotional states associated with the “come-down” from ecstasy 
(Winstock et al., 2001) (or with serotonin (5-HT) depletion due to chronic use (Green et al., 2003; 
Morton, 2005). In addition, many users also report taking cannabis during the initial acute 
stimulatory phase in order to “improve its effects“ and obtain a more “mellow” experience on 
Ecstasy (Boys et al., 2001). 
The behavioral and neurobiological effects of MDMA (e.g., (Green et al., 2003; Cole and Sumnall, 
2003), or cannabis (e.g., (Hall et al., 2001; Howlett et al., 2004)) have been researched extensively 
and are well documented. However, there is inconsistency in the literature about the effects of a 
combined administration, both in the few human studies investigating cognitive impairments as well 
as in animal studies focusing on behavioral models or the interaction on neurocellular levels. 
Taken acutely, at different incidences, the two substances may have opposing effects (see above), 
whereas when taken chronically their negative effects might be additive (Parrott et al., 2007). In 
both cases, interaction of their effects might take place both on a psychological as well as 
neurobiological level.  
The aim of this review is, firstly, to provide a short overview on the latest human research 
concerning cognitive effects of co-consumption of MDMA and cannabis. Although Ecstasy users 
ingest pills with an unknown amount of the main psychoactive compound MDMA, the amount of 
MDMA in Ecstasy  pills has increased within the last decade (Parrott, 2004; 2010). For the sake of 
clarity, the term MDMA users will be used for human ecstasy users throughout this review. 
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Key learning objectives 
1 Ninety to ninety eight percent of MDMA users concomitantly smoke cannabis.  
2 In chronic MDMA+cannabis users, impairments in various memory functions, 
impulsivity and decision making have been found. Whether these drugs can be 
allocated to specific deficits remains unclear. Frequency, duration and pattern of co-
consumption may influence the impact of either drug. 
3 Experiments in rodents demonstrate various behavioural effects, presumably due to  
interaction of the endocannabinoid system and 5-HT/DA in  various brain regions: 
a) Acute rewarding effects of MDMA (number of lever presses, CPP) are most 
likely regulated by interaction with CB1 receptors and DA in the nucleus 
accumbens. 
b) Disruption of memory function by co-administration of MDMA and THC, and 
the reversal of MDMA-induced working memory deficit by a CB1 antagonist 
points to an interaction of MDMA-induced neurotransmission and CB1 
receptor activation in the hippocampus. 
c) Hyperthermia, anxiety and depletion of 5-HT in prefrontal cortex, 
hippocampus, and amygdala due to MDMA administration was prevented 
by THC and a CB1 agonist. 
Research with human polydrug users typically tests for cognitive abilities after prolonged and past 
drug use. There are only very few studies examining acute effects of the co-consumption of MDMA 
and cannabis. Secondly, a more elaborate picture of the state of knowledge about the interaction 
of cannabinoid agents and MDMA in animal studies will be given. Here, research predominantly 
focuses on the acute effects of co-administration, or on long-term consequences on a cellular level, 
and less studies are known which examine chronic effects on behavior or cognition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This review was compiled by classical systematic literature research using the scientific search 
engine PubMed (search terms included “MDMA” OR “ecstasy” + “cannab*” OR “cannabis” + 
“cognition” OR “behavior”). Studies focusing on use or administration of only one of the substances 
were excluded. The following overview includes 23 studies published between 2002 and 2010 with 
an explicit focus on MDMA plus cannabis use or cannabinoid agent administration. Conclusions 
and implications for further research will be discussed. 
 
MDMA+Cannabis: effects on higher cognitive functions  
 
This section describes human studies focusing on cognitive functions or the impairments thereof 
after MDMA and cannabis co-consumption. The vast majority of studies examines long-term, 
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chronic (poly-) drug users in a retrospective manner, thus those will receive most attention. 
Furthermore, one study examining the acute effects of co-consumption is described.  
In a study examining executive functions of abstinent polydrug users, multiple regression analysis 
yielded that severity of MDMA use was inversely correlated with performance on a working 
memory and analogical reasoning task, whereas severity of cannabis use predicted cognitive 
flexibility (Verdejo-Garcia et al., 2005). However, Morgan et al. (2006) showed that former MDMA 
users also perform worse on measures of impulsivity and decision making than polydrug users 
(any illicit drug other than MDMA) or drug-naïve controls. Furthermore, MDMA users seem to have 
more problems in complex learning tasks (Brown et al., 2010), processing speed (de Sola et al., 
2008) and implementation of control strategies (Roberts and Garavan, 2010) than cannabis users. 
In a recent review examining whether certain cognitive impairments can be attributed to specific 
drugs, it was noted that MDMA and cannabis use has a robust effect on spatial processing and 
complex planning (Fernandez-Serrano et al., 2011). On the other hand, Fisk et al. (2006) found 
that MDMA+cannabis users performed equally to MDMA users, and both groups were worse than 
controls, on measures of associative learning, verbal and visual-spatial working memory and 
reasoning. A study with MDMA+cannabis and only cannabis users by Croft et al. (2001) showed 
that neuropsychological deficits in learning, memory, and verbal word fluency were related to 
cannabis consumption, rather than MDMA consumption, as there was no difference in 
performance between the two groups. Only in the Stroop test (a measure for impulsivity/speed of 
processing) did the MDMA+cannabis group perform worse than the cannabis only consumers. 
Notably, both groups performed significantly worse than the control (drug naïve) group in the 
different cognitive functions tested (Croft et al., 2001). Furthermore, cannabis users showed 
significant deficits in memory function as well as word free-call regardless of concomitant MDMA 
use (Dafters et al., 2004; Clark et al., 2009), and impairment on a measurement for impulsivity 
compared to MDMA users and controls (Clark et al., 2009). Thus, some cognitive impairments 
previously attributed to MDMA use in fact could be caused by (unreported) cannabis abuse 
(Lamers et al., 2006). In line with this, self-reported psychological impairments of MDMA users 
were found to be mainly associated with regular concomitant cannabis use (Daumann et al., 2004). 
However, MDMA use was shown to have significant dose-related negative effect on verbal delayed 
recall after adjusting for the use of other drugs (Schilt et al., 2008), and in a meta-analysis including 
45 recent studies, it was found that MDMA users performed significantly worse in verbal short- 
term and working memory than polydrug control groups (Nulsen et al., 2010).  In line with this, 
poorer performance of heavy MDMA polydrug-users on a memory test was attributed to the extent 
of Ecstasy use only (Gouzoulis-Mayfrank et al., 2003). One explanation of these distinct findings 
could be that cannabis consumers self-report problems with short-term and prospective memory 
(Solowij and Battisti, 2008), whereas MDMA users complain about long-term memory deficits 
(Murphy et al., 2009). Another explanation of these effects is drug-induced neurobiological change 
in distinct areas of the brain responsible for different mental capacities. Imaging studies with 
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humans (for review, see (Howlett et al., 2004)) and animal studies (Scallet, 1991) show structural 
and/or functional impairment in the hippocampus (a cannabinoid receptor type 1 (CB1) rich area 
implicated in memory) after chronic cannabis consumption, and serotonin (5-HT)  and serotonin 
transporter (SERT) deterioration in the (pre)frontal cortex (implicated in planning and executive 
functions) of chronic MDMA users (e.g., (Reneman et al., 2001; Lundqvist, 2010)). Depending on 
amount and frequency of co-consumption, long-term polydrug use therefore may lead to additive 
neuropsychological impairment. Only one study examined the acute effects of co-administration: 
Dumont et al. (2010) conclude from a variety of psychomotor, memory and subjective effects tests, 
that overall “cognitive impairments induced by acute administration of THC was more robust 
compared with MDMA, and co-administration did not exacerbate single drug effects on cognitive 
function” (Dumont et al., 2010), yet the participants were experienced users of both drugs.  
Summing up, the literature on the contribution of cannabis on long-term cognitive effects of MDMA 
abuse is somewhat inconsistent. Whereas some studies report memory deficits to be mostly 
attributable to cannabis consumption, MDMA abuse is generally associated with control-related 
functions (but see (Nulsen et al., 2010). It might be suggested that the pattern of cannabis 
consumption (light or heavy use) influences the (lifetime-consumption-dependent) MDMA-induced 
cognitive problems. However, most human studies cannot rule out additive effects, and different 
control groups between studies (i.e., drug-naïve vs. MDMA-naïve) complicate direct comparisons 
(but see (Nulsen et al., 2010)). In addition, amount and frequency of consumption differ between 
the two drugs and between drug users (Gouzoulis-Mayfrank and Daumann, 2006b) (for example, 
purity of Ecstasy tablets taken on any previous occasion is unverifiable). Furthermore, caution 
needs to be exerted when interpreting self-reported symptoms of (former) long-term drug users, as 
these can be related to any of the substances used, and distorted by e.g., memory problems or 
resulting or pre-existing psychiatric impairments. However, it is still worthwhile to consider studies 
in which subjects have previously used both drugs, in order to find out about the impact of the 
frequent combination of these drugs on complex executive functions and combine this information 
with animal research investigating the underlying neurological effects.  
 
MDMA+Cannabinoid agents: behavioral effects & neurobiological interactions  
 
In contrast to human studies, animal research allows for exact monitoring of dose and combination 
of unadulterated substances as well as a clearer establishment of cause-and effect. The following 
section describes studies examining behavioral and neurobiological effects of co-administration of 
MDMA and cannabis or cannabinoid agents. Most animal studies focus on acute effects of these 
substances, therefore those make up the majority of works depicted.  
In the same way that different cannabinoid ligands are a great advantage to study detailed effects 
of cannabis consumption, the use of various cannabinoid agents can also be a confounding issue. 
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Depending on the design and aim of the study, these could be delta9-tetrahydrocannabinol (∆9-
THC, the main psychoactive ingredient derived from the cannabis plant), or synthetic cannabinoids 
with distinct affinities to the CB receptors, like WIN55,212-2 (a CB1 receptor agonist), CP55,940 (a 
CB1 and CB2 receptor agonist) or SR141716A and AM251 (CB1 receptor antagonists). Each 
agent only mimics part of the effects evoked by the mixture usually inhaled by human cannabis 
consumers, and provides specific and therefore limited information about neurobiological 
interaction with MDMA. Furthermore, route of administration and therefore pharmacokinetics, differ 
between animal and human studies (e.g.,(Green et al., 2009)), and systemic administration of 
MDMA and any cannabinoid agent to animals only allows for speculation regarding the 
neurocellular mechanisms. However, in vitro studies have shown that MDMA and cannabis 
administration leads to metabolic and neurotransmission alterations in prefrontal and subcortical 
brain areas responsible for distinct components of executive functioning, (Nagayasu et al., 2010; 
Fiaschi and Cerretani, 2010; Sarne and Mechoulam, 2005; De Petrocellis and DiMarzo, 2010) 
presumably by interaction of CB1 receptor activity and serotonin (5-HT) or dopamine (DA). For 
example, in the prefrontal cortex, 1/3 of axon terminals co-express CB1 receptors. Acute 
administration of SR141716A increases extracellular release of 5-HT and DA, whereas subchronic 
or chronic treatment with WIN55,212-2 causes a persistent reduction of DA in the rat prefrontal 
cortex (Lopez-Moreno et al., 2008). In the nucleus accumbens, ∆9-THC significantly decreased 5-
HT and glutamate release, and this effect was reversed by the CB1 antagonist SR141716A (Sano 
et al., 2008). In contrast, DA release was increased in this brain structure upon intravenous 
administration of WIN55,212-2 (Lopez-Moreno et al., 2008).  
In rodents, some evidence shows regulative effects of separate or co-administration on various 
behavioral measures. In CB1 knock-out mice, pre-treatment with ∆9-THC prevented MDMA-
induced hyperthermia and decreased acute responses to MDMA (increased locomotor activity, 
body temperature, and anxiousness). CB1 knock-out mice still showed a place preference for 
MDMA, however they failed to self-administer any dose up to 0.25 mg/kg  (Tourino et al., 2010). 
Another study demonstrated that a low dose (0.1mg/kg) of WIN55,212-2 increased rewarding 
effects of MDMA, whereas a higher dose (0.5mg/kg) decreased MDMA-induced conditioned place 
preference in mice (Manzanedo et al., 2010).  
One review describes some of the interactive effects of MDMA with cannabinoid agents in rats. In 
intracerebroventricular (i.c.v.) self-administration studies, CP55,940 decreased the number of lever 
pressings to obtain MDMA  (Sala and Braida, 2005). In contrast, pre-treatment with SR141716A 
increased MDMA-associated lever pressings and also MDMA-induced conditioned place 
preference (Braida et al., 2005; Braida and Sala, 2002). It seems likely that the endocannabinoid 
system influences the mechanisms regulating the reinforcing effects of MDMA, possibly via 
modulation of DA transmission by presynaptically located inhibitory CB1 receptors (Braida and 
Sala, 2002). Overlapping of CB receptors and DA receptors has been shown, for example in the 
nucleus accumbens, and stimulation of CB1 receptors might produce additional reinforcing effects. 
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However, acute attenuation of short-term memory via stimulation of CB1 receptors in the 
hippocampus could also result in a reduction of time spent in the compartment previously 
associated with MDMA. Taken together, these studies point to an endocannabinoid control of the 
acute rewarding effects of MDMA (Braida and Sala, 2002). Interestingly, MDMA alone affects 
rodent species in distinct ways. In mice, acute administration leads to a strong release of DA and 
to a less pronounced release of 5-HT in various brain regions, whereas the opposite is true for rats 
(Green et al., 2003). Neurobiological markers of presumed neurotoxicity, for example for 5-HT 
neurons (Stone et al., 1987), further support this distinction. For example, Kindlundh-Högberg et 
al., 2007, found reduced binding of dopamine transporter (DAT) of mice, and decreased SERT 
density in rats in the nucleus accumbens shell after repeated intermitted MDMA administration 
(3x5mg/kg). In terms of behaviour rats, but not mice, showed reduced anxiety in the open field test 
(Kindlundh-Högberg et al., 2007). However, there is no difference in measures like body 
temperature and activity (Green et al., 2003). These differential effects of MDMA on brain 
neurotransmission could also influence the outcome of co-administration of cannabinoid agents in 
these species. 
Although memory performance is widely investigated as a primary measure of cognitive capacity in 
human polydrug users, there is only one animal study systematically examining the effect of acute 
co-administration of MDMA and ∆9-THC on mnemonic function (Young et al., 2005). Low and 
moderate dosages (0.25mg/kg ∆9-THC plus 1.25mg/kg MDMA, 0.5mg/kg ∆9-THC plus 2.5mg/kg 
MDMA, respectively) tested in rats disrupted working memory in a double Y-maze task, even 
though the low doses had no effect when administered alone. Another study investigated 
cannabinoid influence on object recognition task performance during withdrawal after repeated 
treatment with MDMA (10mg/kg; daily for seven days) (Nawata et al., 2010). It was found that 
MDMA-induced memory impairment was prevented by co-administration of AM251, as well as by 
single pre-treatment with the CB1 receptor antagonist on the 7th day of withdrawal. Furthermore, 
MDMA- treated CB1 knock-out mice did not show impairments in the object recognition task. 
These two studies point to an interaction of MDMA- induced neurotransmission and CB1 receptor 
changes in the hippocampus. However, they contradict the above mentioned human study 
(Dumont et al., 2010) finding more pronounced acute impairments of memory due to ∆9-THC, 
regardless of co-consumption of MDMA. 
An interaction between the presumably neurotoxic effects of MDMA and neuroprotective potential 
of cannabinoid agents in rats has been demonstrated by Morley et al., 2004, who showed acute 
reversion of MDMA-induced hyperthermia to hypothermia and a potential decrease of MDMA-
induced hyperactivity by co-administration of ∆9-THC or the synthetic cannabinoid receptor agonist 
CP55,940. Weeks after the treatment, a high-performance liquid chromatography (HPLC) analysis 
showed that both ∆9-THC as well as CP55,940 partially prevented the MDMA-induced depletion of 
5-HT and its metabolite 5-HIAA in some brain regions, speculatively by counteracting oxidative 
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Future research questions 
Future research could address the following points: 
 
1. In human studies, special care should be taken to rule out confounding drug-use other 
than MDMA and/or cannabis. Research focusing on the acute effects of co-consumption 
would yield insight into immediate changes and possibly endangering impairments. 
Furthermore, more research examining neurological effects of chronic co-consumption on 
prefrontal and hippocampal brain areas via in vivo imaging techniques would be desirable. 
 
2. Behavioural animal studies should focus on long-term and moderate to heavy co-
administration, and examine a) cognitive deficits via paradigms testing memory, impulsivity 
and decision making, in order to clarify contradictory results from retrospective human 
studies and b) neurocellular changes, especially in regions implicated in the respective 
cognitive functions, focusing on the interaction of serotonin, dopamine and the 
endocannabinoid system. 
stress reactions. Co-administration of the CB1 antagonist SR 141716A, did not have a modulator 
effect (Morley et al., 2004). 
The majority of studies described so far employ a study design adequate to investigate acute 
effects, either of the combination administered simultaneously via injection or infusion, or effects of 
MDMA after pre-treatment with a cannabinoid agent. However, since human studies are usually 
based on retrospective accounts of long-term, chronic co-users, it is worthwhile to take a look at 
animal models employing chronic treatment. There are some studies reporting the effects, both 
behavioral as well as neurological, of prolonged administration of either substance alone and with 
varying treatment regimes (e.g., (Rubino and Parolaro, 2008; Meyer et al., 2008; Wegener and 
Koch, 2009b; Piper et al., 2010)). However, as to current knowledge, there is no realistic chronic 
treatment model co-administering MDMA+cannabis or cannabinoid agents to investigate cognitive 
deficits and underlying causes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summing up, the endocannabinoid system, and especially the cannabinoid receptor type 1, has 
been shown to mediate several effects of psychostimulant drugs of abuse. Animal experiments 
provide substantial evidence for modulator or interactive effects of acute co-administration of 
MDMA and cannabinoid agents both in behavioral paradigms like conditioned place preference 
and body temperature as well as in studies examining neurobiological/-transmitter changes. 
Chronic models of co-administration are sparse. 
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Conclusion  
 
There is some research on the physiological processes involved in simultaneous use of MDMA 
and cannabis regarding acute interaction, but little consensus exists about impairments of higher 
cognitive functions. The contribution of each substance, and their combination, to deficits in 
memory, mood, impulsivity and psychopathologies in human polydrug users is unclear. Studies 
reporting on only MDMA or only cannabis use might focus on drug-specific neuropsychological 
tests and therefore disregard the potential effect of the combination of these drugs. Furthermore, 
especially when it comes to measuring the long-term effects of any drug, it is nearly impossible to 
rule out confounding variables in humans, e.g., purity of ingested substances, or previously 
existing cognitive impairments. Animal studies, on the other hand, not only allow for exact 
monitoring of administration (including modeling polydrug use), but also for equalizing external 
influences. Current literature does express concerns about the differences in frequency of dosing, 
route of administration and dosage exposure between rodent models and human patterns of use 
(Green et al., 2009). Naturally, animal models of consumption and behavioral as well as 
neurobiological changes can only provide indications which have to be confirmed on retrospective 
human studies. But retrospective user reports and cognitive test results are usually based on long-
term co-consumption patterns. However, as of current knowledge, no chronic intermittent animal 
models of the combination MDMA+cannabis in animals exist. Especially changes in higher 
cognitive functions as a consequence of dual intake of these substances, and the possible 
underlying cellular mechanisms have not been investigated in suitable long-term animal studies.  
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Acute Co-administration of the Cannabinoid Receptor Agonist WIN55-212,2  does 
not influence 3,4-methylenedioxymetamphetamine (MDMA)-induced Effects on 
Effort-based Decision making, Locomotion, Food intake and Body temperature 
 
Sybille Schulz, Jannis Gundelach, Heta K. Svärd, Linda Hayn, Michael Koch 
Abstract 
 
3,4-methylenedioxymethamphetamine (MDMA) and cannabis are illegal drugs that are frequently 
co-consumed in western societies. This study investigated the acute behavioural effects of co-
administration of MDMA and the synthetic cannabinoid receptor agonist WIN55,212-2 (WIN) in 
rats. Four treatment groups were tested: MDMA (7.5.mg/kg, s.c.), WIN (1.2mg/kg, i.p.), combined 
administration (MDMA+WIN), and vehicle control. Following pre-training, animals were tested in a 
T-maze effort-based decision making task. Body temperature was measured at three time points. 
Separated by one week wash-out periods, rats were tested for locomotor and exploratory activity in 
an open field, as well as food intake under the same between subjects treatment schedule. Acute 
MDMA administration impaired effort-based choice behaviour, indicating immediate effects of 
consumption on decision making ability. MDMA and MDMA+WIN treatment increased body 
temperature to a similar extent, whereas WIN alone increased temperature at an earlier time point. 
Locomotor activity and exploratory behaviour, as well as food intake was similar (and significantly 
different from vehicle controls) in MDMA and MDMA+WIN-treated animals. MDMA-induced 
decreased exploration anxiety behaviour in the open field was diminished by WIN, whereas WIN 
alone had no effect. In summary, acute co-administration of a cannabinoid receptor agonist did not 
substantially modulate MDMA-induced behavioural effects in rats.  
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Introduction 
 
Polydrug use has become a challenging issue in research involving human drug users (EMCDDA, 
2010). For example, most 3,4-methylenedioxymetamphetamine (MDMA) users are polydrug users 
(Danielsson et al., 2011). Cannabis is the most frequently taken illegal co-drug: 98% of a 
representative sample of MDMA users concomitantly use cannabis (Wu et al., 2009; Parrott et al., 
2007). Combined effects on physiological, behavioural and cognitive measures are difficult to 
disentangle and may depend on frequency, duration, and amount of co-consumption. In addition, 
many human studies involve chronic and/or heavy polydrug users, thus causal relationships 
between single drugs and their effects are hard to discern. Many MDMA users report smoking 
cannabis concomitantly to enhance positive sensations (for example, euphoria, empathy, 
prosocial behaviour, energy) or some time after MDMA consumption to alleviate adverse effects 
(anxiety, depression, anhedonia and agitation) of the “come-down” (Parrott et al., 2004; Boys et 
al., 2001). 
Acute MDMA administration leads to a transient, dose-dependent release and reuptake inhibition 
of the neurotransmitters serotonin (5-hydroxytryptamine, 5-HT) and dopamine (DA) and to a lesser 
extent noradrenaline (NA) and acetylcholine (ACh) (Cole and Sumnall, 2003), particularly in the 
medial prefrontal cortex (mPFC), striatum and hippocampus (Green et al., 2003; Mechan et al., 
2002). Increased 5-HT transmission contributes to the behavioural effects of MDMA in a complex 
way which additionally seems to depend on the interaction with DA transmission (Bankson and 
Cunningham, 2001). In accordance with reported effects in human users, acute effects of MDMA-
administration in animals include hyperthermia (Docherty and Green, 2010), hyperlocomotion 
(Morley et al., 2004), anxiety (Cole and Sumnall, 2003), and hypophagia (Frith et al., 1987; 
DeSouza et al., 1997). Few studies have tested the acute effects on more complex behaviour. A 
decrease in impulsivity in humans (Vollenweider et al., 1998) as well as a dose-dependent 
increase of lever pressings for reinforcement in animals (Byrne et al., 2000) was shown after 
MDMA administration.  
In contrast, the main psychoactive compound of cannabis, delta9-tetrahydrocannabinol (delta9-
THC, THC) acts as an inhibitory transmitter on presynaptic cannabinoid type 1 (CB1) and type 2 
(CB2) receptors within the endocannabinoid system. Activation of CB1 receptors seems to 
modulate neurotransmission (Wilson and Nicoll, 2002). In the CNS, a high abundance of CB1 
receptors has been found in basal ganglia, cerebellum, olfactory bulb and hippocampus, moderate 
density appears in cortical areas (Herkenham et al., 1991). Results from acute studies in animals 
employing THC, or one of the more potent synthetic CB1 receptor agonists (e.g., WIN55-212,2, 
CP55,940) or antagonists (e.g., SR171416) support reports obtained from human studies in that 
cannabinoids are implicated in the acute regulation of several physiological processes. For 
example, acute consumption of THC increases heart rate and, impulsive responding on certain 
tasks, decreases postural stability and alertness and influences time-estimations in humans 
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(McDonald et al., 2003; Zuurman et al., 2009). In animals, activation of CB receptors increases 
food intake and heart rate, dose-dependently affects locomotor behaviour and decreases body 
temperature (Elphick and Egertova, 2001; Ameri, 1999; Iversen, 2003). 
Behavioural and neurobiological effects of sole administration of MDMA or cannabis are well 
documented (for review see (Green et al., 2003; Morton, 2005; Howlett et al., 2004)) and some 
studies examine the long-term cognitive consequences of co-consumption of these drugs (Croft et 
al., 2001; Rodgers et al., 2001; Daumann et al., 2004). Literature on the consequences of acute 
co-consumption is less thorough. One human study demonstrated mixed effects: co-administration 
of cannabis prolonged the onset and duration of MDMA-induced increases in temperature, but had 
no additive influence on deficits in memory. THC induced psychomotor impairments independently 
of MDMA (Dumont et al., 2009). Positive subjective ratings were increased for the combination of 
the drugs compared to each drug effect alone (Dumont et al., 2010). Some evidence from rodent 
studies shows regulatory effects of co-administration on locomotion, body temperature, and 
reinforcing effects. For example, prevention of MDMA-induced hyperthermia, anxiety, and a 
decrease of MDMA-induced hyperactivity due to of THC was observed in rats (Morley et al., 2004). 
Impairment of working memory upon co-administration of low and medium doses of MDMA plus 
THC was shown (Young et al., 2005). In terms of reinforcing properties, intracerebroventricular 
(i.c.v.) self-administration studies demonstrate a modulation of MDMA-induced reinforcing effects 
(self-administration or conditioned place preference (CPP)) by cannabinoid agents (Sala and 
Braida, 2005; Braida and Sala, 2002). In mice, exposure to WIN in adolescence later facilitated 
MDMA-induced CPP (Rodriguez-Arias et al., 2010) or potentiated the rewarding effects of MDMA 
(Manzanedo et al., 2010). In the latter study, the CB1 antagonist SR171416 did not block the 
effects of WIN. Furthermore, in CB1-knock-out mice, pre-treatment with THC still prevented 
MDMA-induced acute responses (Tourino et al., 2008), pointing towards a CB1-independent 
mechanism of interaction. The effects of acute co-administration on cognitive tasks, for example 
choice behaviour, have not been investigated.  
This study aimed to further elucidate the interactive effects seen after acute co-administration of 
MDMA and Cannabis. The synthetic specific CB receptor agonist WIN55,212-2 (WIN) was used to 
investigate interactions of MDMA and CB receptor stimulation, aiming to narrow the range of 
effects of THC in the central nervous system. For the first time, the effect of acute MDMA 
administration as well as the combined administration of MDMA and a cannabinoid agonist on 
effort-based choice behaviour is investigated, in addition to locomotion, food intake and body 
temperature measures.  
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Materials & Methods  
 
Animals 
 
In total, 39 adult naive male Wistar rats (Harlan, Borchen, Germany) weighing 230-300 grams were 
used in these experiments. Upon arrival, animals were allowed to habituate for 4-5 days in a 
vivarium under standardized conditions (4-6 animals per Makrolon type IV cage; tap water ad 
libitum; 12 hour light/dark circle, lights on at 7am; temperature 22 +/-2°C) and were handled 
regularly. During the habituation and handling period, standard lab chow was available ad libitum. 
Controlled feeding (12g/animal/day) started two days before the first training session. All animal 
experiments were conducted in accordance with the principles of animal care and the international 
laws on animal experiments (Directive 2010/63/EU) and were approved by the local authorities. 
 
Drugs 
 
All drugs were prepared freshly before administration and were injected in a volume of 1ml/kg. 
WIN55,212-2 (SIGMA-Aldrich, Steinheim, Germany) was dissolved in 2% Tween®80 (Serva, 
Heidelberg, Germany) and 98% NaCl solution (0.9% NaCl, Fresenius Kabi GmbH, Bad Homburg, 
Germany) and injected at a dose of 1.2mg/kg, intraperitoneally (i.p.). MDMA hydrochloride 
(synthesized in the Institute of Inorganic Chemistry, Prof. Nagel, University of Tübingen. Identity 
and chemical purity was verified) was dissolved in phosphate buffered saline (PBS), stabilizing a 
well-tolerated pH-value of the solution, and injected at a dose of 7.5mg/kg, subcutaneously (s.c.). 
PBS injection served as vehicle control. Single doses which have been shown to be behaviourally 
relevant  (Young et al., 2005; Drews et al., 2005) were chosen in order to minimize the number of 
animals used in this study. 
 
Behavioural tests 
 
Behavioural testing was conducted in a between subjects design. Each treatment group consisted 
of 10 rats, except the combination (MDMA+WIN) group (n=9). Each animal underwent the same 
training and testing procedures. However, the sequence of tests was altered in order to minimize 
the influence of repeated substance administration and previous behavioural tasks. All animals 
started with training and subsequent testing in the effort-based decision making task. Half of each 
treatment group was tested in an open field one week later, followed by a food preference test 
another week later. The second half of the group underwent the food preference task first, followed 
by the open field tests. After each test, a wash-out period of seven days was allowed for all 
animals. Contrary to other reports (Chaperon and Thiebot, 1999), there were no observable 
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adverse effects upon first, or subsequent, exposure to the cannabinoid agonist. MDMA was 
administered 30 minutes and WIN 10 minutes prior to testing, thereby allowing examination of 
behaviour during the peak time of effect. The combined treatment was timed in such a way that the 
peak time of the effects accumulated at the time of testing. Half of the control (vehicle) group (n=5) 
was injected 10 minutes, the other half (n=5) 30 minutes prior to testing.  
Effort-based decision making 
 
The effects of MDMA, WIN, and the combination of both drugs on effort-based decision making 
were tested in a T-maze paradigm. This task allows monitoring of cost-benefit choice behaviour, 
i.e., how much effort the animal is willing to exert to obtain a (larger) reward. At the end of the 
reward arms of the T-maze (measurements of each arm: 60 cm x 15 cm x 30 cm (L x W x H)) 
either two or four pellets (Bio-Serv©, UK Dustless Precision Pellets©, 45mg) were placed in a 
metal food well. While the arm containing two pellets (low reward arm, LR) was freely accessible 
for the rats, a 30 cm barrier made of wire mesh was placed in the arm containing four pellets (high 
reward arm, HR). The HR was the right side T-maze arm for half of the animals, and left side for 
the other half. All animals were habituated to the apparatus as well as to increasing heights of the 
barrier and pre-trained until as a group they reached baseline level of ≥ 80% choice of HR for three 
consecutive days. Intertrial interval (ITI) was 1 min. Habituation and pre-training sessions took 
place once a day for an average of 16 days (for further detail on apparatus and training method 
see (Walton et al., 2002), adapted from the original study by Salamone (1994)). For the test the 
animals received drugs or vehicle as described above and performed two forced choice runs (one 
to each arm, in pseudo-randomized order), prior to ten free choice runs. The percentage of choices 
for the HR arm was calculated for each treatment group. 
Body temperature 
 
Temperature was measured with an in-ear thermometer (Thermoscan, IRT3020 CO, Braun, 
Switzerland) at three different time points: A baseline measurement one day before the first testing 
in the effort-based task was done in order to rule out effects of the injection procedure. A second 
measurement was done before the animals were tested (i.e., at the respective peak times of 
effects of the substances, T1), and a third time 1 hour after the test (T2). At each time point, 
temperature was measured three consecutive times, and the mean of these three measures was 
considered the temperature value for that time point. 
Locomotor activity  
 
Animals were placed in infrared beam-controlled acrylic glass chambers (ActiMot-system; TSE, 
Bad Homburg, size: 44.7 cm x 44.7 cm x 44 cm) measuring horizontal and vertical locomotion. 
Locomotion and exploratory behaviour was automatically recorded by a PC (ActiMot Software; 
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TSE, Bad Homburg) for 35 minutes and stored as aggregated data in seven intervals. Parameters 
analysed were number of rearings, total activity (%), and time spent in centre (%) per 5-minute 
interval. 
Food preference test 
 
Animals were placed in a standard Makrolon type II cage with two glass food wells each containing 
pellets (Bio-Serv©, UK Dustless Precision Pellets©, 45mg) or breeding chow (Altromin, Lage, 
Germany). Breeding chow and pellets only differed in palatability, not in protein (22.5%, 18.7%, 
respectively) or fat (5%, 5.6%, respectively) content. Animals were allowed to free-feed for 10 
minutes. Animals had not eaten for 20 (+/-2) hours when testing was conducted. Mass of eaten 
food was weighed for each animal. 
 
Data analysis 
 
For statistical analysis, analyses of variance (ANOVAs) were conducted with SigmaStat2.03 for 
Windows (SPSS Inc., Chicago, IL, USA), followed by post hoc Tukey tests for pairwise multiple 
comparisons. For all measurements, p<0.05 was considered a significant difference. 
 
Results 
 
Effort-based decision making 
 
One animal from the MDMA+WIN group was unable to complete the task and therefore was 
excluded, thus yielding n=10 for MDMA, WIN and vehicle groups, and n=8 for the MDMA+WIN 
group for the statistical analysis. MDMA- and MDMA+WIN-treated animals chose the high reward 
arm (HR) less often compared to the WIN and vehicle groups (51% and 57% vs. 82% and 95%, 
respectively, Fig.1). A one-way ANOVA yielded a significant difference of HR choices between 
treatment groups [F(3,34)= 3.50, p=0.026]. The post-hoc test revealed a significant difference 
between the vehicle and MDMA group (mean HR choice= 95%, 51%, respectively, p=0.034). While 
the combined treatment (MDMA+WIN) reduced choices for the HR, this effect failed to reach 
significance (p=0.117).  
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Fig.1: Effects of acute MDMA (n=10), WIN (n=10), MDMA+WIN (n=8) and vehicle (n=10) administration on 
effort-based decision making. Bars depict the percentage means (+SEM) of HR choices (large reward 
obtained by climbing the 30cm barrier) during the behavioral test sessions. Closed square denotes p<0.05 
compared to vehicle.  
 
Body temperature 
 
One hour after behavioural testing (T2), body temperature was increased in rats treated with 
MDMA (mean: 37.4°C) and MDMA+WIN (mean: 37.5°C) compared to baseline (BL) and to 
measurements 30 minutes after administration (T1). WIN-treated animals showed an increase in 
temperature 10 minutes after administration (37.3°C, BL: 36.6.°C; Fig.2). A two-way ANOVA 
yielded a significant effect of time point of measurement [F(2,44)=15.41, p<0.001] as well as a 
significant interaction of time point x substance (F(6,44)= 3.40, p=0.008]. Post-hoc test revealed 
significant differences comparing treatment groups MDMA+WIN vs. WIN measured before the first 
run (T1) (p=0.007). Furthermore, significant differences were found within MDMA and MDMA+WIN 
groups between measurements taken one hour after behavioural testing (T2) and BL (p=0.001 and 
p<0.001) as well as between T1 and T2 (p=0.017 and p<0.001). Within the WIN group, the 
difference between T1 and BL was significant (p<0.001). 
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Fig.2: Effect of administration of MDMA (n=10), WIN (n=10), MDMA+WIN (n=9) and vehicle (n=10) on body 
temperature (°C). Data are means (+SEM) of three measurements for each animal at each time point. 
Closed triangle denotes significant difference (p<0.05) compared to WIN at T1; open symbols represent 
differences within the same treatment group compared to T1 (circle) or T2 (rhombus and square)  (p<0.001). 
 
Locomotor activity and exploratory behaviour 
 
MDMA and MDMA+WIN-treated animals showed an increase in activity (mean: 63% and 61%, 
respectively) as well as  in number of rearings (mean: 53 and 43, respectively), compared to the 
WIN (20% and 12) or vehicle (20% and 18) group (Fig.3). In addition, MDMA-treated rats spent 
more time in the centre of the open field than the remaining three treatment groups (mean: 15% vs. 
8% (MDMA+WIN), 4% (WIN) and 6% (vehicle)). For locomotor activity, a two-way ANOVA yielded 
significant effects of treatment group [F(3,244)= 310.74, p<0.001], time interval [F(6,244)= 27.46, 
p<0.001], and interaction of substance x time interval [F(18,244)= 2.18, p=0.004]. Post-hoc test 
revealed significant differences between MDMA and MDMA+WIN groups compared to WIN- and 
vehicle-treated groups (p<0.001) over all 35 minutes, as well as within each 5-minute time interval 
(p<0.001). WIN- and vehicle-treated animals significantly reduced their activity between the first 
and all subsequent intervals (p<0.001), as well as between the second and the second last (WIN, 
p=0.05) or the third last (vehicle, p=0.011) intervals.  
A two-way ANOVA comparing the number of rearings yielded significant effects for substance 
[F(3,244)= 73.56, p<0.001] and time interval [F(6,244)= 3.24, p=0.004]. Post-hoc test revealed 
significantly increased number of rearings for the MDMA group compared to the other three 
treatment groups (p<0.001 (WIN and vehicle), p=0.021 (MDMA+WIN)), as well as for the 
MDMA+WIN group compared to the WIN and vehicle groups (p<0.001). 
In terms of differences within time intervals, MDMA-treated animals reared significantly more often 
than WIN- and vehicle-treated groups in all but the very first time interval (p<0.001 to p=0.006). 
MDMA+WIN-treated animals reared significantly more often than both WIN- and vehicle-treated 
animals in the last three  intervals (p<0.001) and the third interval (p=0.029; p=0.044, respectively), 
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as well as compared to WIN during the second and fourth interval (p=0.003 and p=0.042, 
respectively). Vehicle-treated animals showed a reduction in the number of measured rearings 
between the first and third to seventh time interval (p<0.001 to p=0.025) (For significant differences 
(p<0.001) within the time intervals, see Fig.3). A two-way ANOVA analysing the time spent in the 
centre of the open field yielded a significant effect for substance [F(3,244)=17.88, p<0.001]. Post-
hoc test confirmed that MDMA-treated animals spent significantly more time in the centre 
compared to all three remaining treatment groups (p<0.001). 
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Fig.3: Effects of MDMA, WIN, MDMA+WIN and vehicle (n=10;10;9;10, respectively) on locomotion (a), 
exploratory (b) and anxiety-like (c) behaviour. (a) and (c) are depicted as % of time of 5-minute intervals for a 
total of 35 minutes, (b) as absolute number of rearings per interval. Significant differences of p<0.001 are 
depicted only. Open triangles and open circles indicate differences between the first and the denoted time 
interval within vehicle and WIN groups, respectively. Closed triangles and squares denote differences 
between MDMA vs. WIN and vehicle groups, respectively. Closed circles and rhombuses indicate 
differences between MDMA+WIN and WIN and vehicle groups, respectively. 
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Food preference test 
 
All animals consumed more pellets than breeding chow. When comparing the amount of pellets 
consumed, MDMA- and MDMA+WIN-treated animals ate less than the vehicle and WIN-treated 
groups (mean: 4.5 and 2.8 grams vs. 6.0 and 6.8 grams, respectively) (Fig.4). A two-way ANOVA 
yielded significant effects for type of food [F(1,70)=167.66, p<0.001], substance [F(3,70)=6.14), 
p<0.001], and the interaction substance x type of food [F(3,70)= 4.88, p=0,004]. Post-hoc tests 
revealed that all animals preferred pellets over breeding chow (p<0.001). Rats from the vehicle 
group consumed significantly more pellets than the MDMA (p=0.017) and MDMA+WIN group 
(p<0.001). WIN-treated animals consumed significantly more pellets than the MDMA+WIN group 
(p<0.001). When comparing total amount of food intake, vehicle and WIN-treated groups ate 
significantly more than MDMA+WIN-treated animals (p=0.004 and p=0.002, respectively). 
MDMA+WIN-treated animals consumed less food than MDMA-treated animals (2.8grams vs. 4.7 
grams), however this difference was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: Effects of acute administration of MDMA, WIN, MDMA+WIN and vehicle (n=10;10;9;10, respectively) 
on food preference and intake. Closed square shows significant difference (p<0.005) in total food intake 
compared to vehicle and WIN groups; hash symbol denotes difference (p<0.001) in amount of pellets 
consumed compared to vehicle and WIN groups; asterisk shows difference (p<0.05) in amount of pellets 
consumed compared to vehicle group. 
 
Discussion 
 
Various studies suggest an interaction of MDMA influence on different neurotransmitters and the 
inhibitory effects of CB receptors on transmitter release in a range of brain regions. For example, 
the synthetic CB1 receptor antagonist SR141617A increased serotonergic and dopaminergic 
neurotransmission, especially in the mPFC (Darmani et al., 2003), whereas THC decreases 5-HT 
neurotransmission in the nucleus accumbens (Sano et al., 2008; Lopez-Moreno et al., 2008). 
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Furthermore, CB1 receptors are expressed on 5-HT and DA neurons not only presynaptically, but 
also on dendrites, and may interfere with the serotonin transporter (SERT) and dopamine 
transporter (DAT) (Lau and Schloss, 2008). The abundant and overlapping distribution of CB1 
receptors may indirectly alter activity of dopaminergic and serotonergic neurons by influencing 
GABAergic inhibition of DA neurons (Pistis et al., 2001). An effect of WIN on glutamatergic (Shen 
et al., 1996) and cholinergic  (Gessa et al., 1998) synapses has been shown as well, offering 
further sites for interaction. Therefore, the DA and 5-HT release and reuptake inhibition properties 
of MDMA would hereby interact with the inhibitory effects of WIN via the CB1 receptor and result in 
opposing, additive or regulative effects in motivation and effort, as well as temperature regulation 
and locomotor behaviour. 
Effort based decision making 
 
MDMA impaired choice behaviour based on effort irrespective of co-administration of WIN. As far 
as to current knowledge, no previous study has investigated the effect of acute MDMA 
administration on effort-based choice behaviour. Exact mechanisms on how MDMA-induced 
alterations in 5-HT and DA release could influence the fronto-striatal circuitry (Floresco et al., 2008) 
or DA release in the nucleus accumbens (Assadi et al., 2009) responsible for regulating effort-
based choice remain speculative. The impact of central 5-HT release on general aspects of 
behaviour, e.g. motivation, may be important here. Furthermore, acute MDMA administration did 
not impair locomotion, but decreased food intake (see below). Therefore, increased 5-HT release 
might have decreased appetite and thus, motivation for climbing the barrier to obtain the high 
reward. Whatever the underlying causes, our data indicates that acute MDMA effects do not only 
include physiological responses like hyperthermia or increased activity, but may also immediately 
impair cognitive functions like decision making. 
Although only MDMA-alone significantly differed from the control group, responses of the 
combined treatment group closely paralleled those of MDMA-treated animals. The lack of a 
significant effect is probably due to side effects observed in the MDMA+WIN-treated animals such 
as increased head waving, defecation, salivation and overall slow responses and movements. One 
MDMA+WIN-treated animal was excluded from the analysis due to inability to move further than 
the decision point of the T-maze. These impairments may have been adverse effects upon the first 
simultaneous administration of MDMA and WIN, as this behavioural pattern was not, or to a lesser 
extent, observed in subsequent experiments. Young et al. (2005) reported similar behavioural 
impairments upon combined administration of THC (1mg/kg) and MDMA (5mg/kg) in a within 
subjects design. As in our study, no major adverse effects of administration of either MDMA or the 
cannabinoid agonist alone were evident, thus observed impairments seem to be due to the 
combination, not the single doses, of the substances. Overall, and especially taking into account 
the observed side effects of co-administration, it is not possible to draw firm conclusions about the 
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influence of the combined consumption on effort-based decision making based on these results. 
However, MDMA-administration seems to have an effect on effort-based choice behaviour with or 
without WIN co-administration.  
Our results show no effect of WIN (1.2mg/kg) on effort-based decision making in rats. This 
contrasts with an earlier study employing operant chambers showing that acute treatment with 
1.2mg/kg or 1.8mg/kg WIN significantly reduced the number of lever presses for pellets (“break 
point“) in a progressive-ratio task compared to a lower dose of WIN (0.6mg/kg) or vehicle 
treatment. Moreover, a significant decrease in the total number of lever presses was detected, 
indicating a complex role of cannabinoids in reward-related behaviour (Drews et al., 2005). 
However, although both paradigms aim at investigating the influence of CB1 activation on effort-
based reward obtainment, there are of course differences between T-maze- and instrumental 
tasks, which preclude a direct comparison. However, our data indicate no influence of CB1 
receptor activation on this behavioural paradigm. 
Body temperature 
 
The present results support previous studies demonstrating an increase in body temperature upon 
consumption of MDMA in humans (Freedman et al., 2005; Mohamed et al., 2011) and rats (Green 
et al., 2003). The peak temperature measured 1 hour after behavioural testing contrasts with 
previous findings showing significant increases compared to baseline levels at 20-30 minutes after 
administration of MDMA (12.5mg/kg, i.p.) (Mechan et al., 2002). However, depending on the route 
of administration (s.c. or i.p. injection) hyperthermic effects can vary in time due to different 
absorption and metabolizing rates. Furthermore, according to Green at al. (2003) peak 
temperatures are also observed 40-60 minutes after i.p. administration.  
Co-administration of WIN did not influence MDMA-induced hyperthermia. Significantly higher 
temperature compared to both baseline and pre-test was measured 1 hour after behavioural 
testing for the MDMA+WIN group. In fact, temperature changes were akin to those seen in the 
MDMA group. These results are in contrast with a finding by Morley (2004), showing that THC and 
CP55,940 prevent MDMA-induced hyperthermia in rats. However, these cannabinoid agents were 
administered according to a different injection scheme (4 x 2.5mg/kg). A study in humans 
demonstrated that THC co-administration does not prevent MDMA-induced temperature increase 
(Dumont et al., 2009). Our results do not support the modulatory role of acutely administered 
CB1/2 receptor ligands on MDMA-induced hyperthermia. Rather, a modulation of the WIN-induced 
rise in temperature by MDMA appears. 
WIN (1.2mg/kg) led to a significant increase in body temperature 10 minutes after administration 
compared to baseline. Earlier studies on cannabinoid effects on body temperature found that low 
doses of THC (0.05 and 0.1 mg/kg) caused hyperthermia, while doses of 1.0, 2.0 and 5.0mg/kg 
induced hypothermia (Taylor and Fennessy, 1977). In contrast to our study, cannabinoid receptor 
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agonists WIN55,212-2 and CP55,940 led to hypothermia, which was reversed by the selective CB1 
receptor antagonist SR141716 (Chaperon and Thiebot, 1999). On the other hand, it was recently 
shown that the endogenous cannabinoid anandamide increases temperature when administered 
intracerebroventricularly (i.c.v.), an effect which is reduced by co-administration of a CB1 receptor 
antagonist (Fraga et al., 2009). Furthermore, low doses of THC significantly reduce, but doses of 
1.0, 2.0 and 5.0mg/kg increase the levels of 5-HT metabolites in the whole brain (Taylor and 
Fennessy, 1977). The dose used in the current study may have had an indirect increasing effect on 
body temperature by elevating 5-HT levels. 
Locomotor activity and exploratory behaviour  
 
MDMA as well as MDMA+WIN treatment significantly increased locomotor activity compared to the 
WIN- as well as vehicle- group (Fig.3a). These effects were stable over the 35 minutes test 
duration and support other studies demonstrating hyperactivity upon acute MDMA-administration 
(Spanos and Yamamoto, 1989; Green et al., 2003). Rats treated with 1.2 mg/kg WIN showed 
activity levels akin to the vehicle group. Co-administration of WIN therefore does not have an 
attenuating effect on MDMA-induced increases in locomotor activity. 
Compared to MDMA-treated animals, MDMA+WIN administration led to a significant overall 
reduction in exploratory behaviour (number of rearings) over the 35 minute measurement (Fig.3b). 
No habituation was observed over time. However, there was no difference when comparing any of 
the individual time intervals. Therefore, co-administration of WIN seems to have a small, if any, 
modulating effect on MDMA-induced exploratory behaviour. In contrast to these results, rodent 
studies administering THC and MDMA found that the cannabinoid had an attenuating effect on 
MDMA-induced hyperactivity in rats (Morley et al., 2004) and mice (Tourino et al., 2008). The 
discrepancy between the previously described and our results may be due to the different test 
paradigms, dose-dependent biphasic effects of cannabinoids  (Chaperon and Thiebot, 1999), and 
a more unspecific effect of THC compared to WIN. 
In terms of the time spent in the centre of the open field, a measure for exploration anxiety, 
MDMA+WIN-, WIN- and vehicle-treated animals spent significantly less time in the centre than 
MDMA-treated animals (see Fig.3c). MDMA seems to have an anxiolytic effect. In contrast, 
increased anxiety levels were found in MDMA-only treated rats (Morley and McGregor, 2000) and 
mice (Ferraz-de-Paula et al., 2011) on various anxiety-related measures. However, this result is 
congruent with Morley et al. (2005) demonstrating decreases of MDMA-induced anxiety by THC, 
measured in an emergence test. The attenuating effect of WIN on MDMA-induced decreased 
exploration anxiety is not due to differences in locomotion as the MDMA+WIN group displayed 
equal levels of hyperactivity to the MDMA group whilst not differing from vehicle group in the 
anxiety measure. Future studies seeking to elucidate the influence of CB1 agonism on (MDMA-
induced) anxiety should employ a more direct measure as well as various CB agents.  
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Rats treated with 1.2mg/kg WIN showed activity, vertical exploratory behaviour as well as 
exploration anxiety levels akin to the vehicle group. Furthermore, there were no differences in 
habituation, i.e. a reduction of activity over the measured intervals within the 35 minutes occurred 
in WIN- and vehicle-treated animals equally. As noted previously, CB1 agonists may have biphasic 
effects according to dose, inducing hyperactivity at low doses and severe motor deficits at larger 
doses (Chaperon and Thiebot, 1999). In line with this, locomotor activity in the open field has been 
reported to be increased by 0.6mg/kg, but not by higher doses of WIN (Drews et al., 2005). A dose 
of 1mg/kg does not affect either ambulation or the frequency of rearings, while higher doses (3 or 
5.6mg/kg) reduce both measures (Jarbe et al., 2006). Various reports point to involvement of CB1 
antagonism (for example, by SR141716), but not agonism, in anxiogenic effects (Moreira et al., 
2009; Rodgers et al., 2005; Patel et al., 2005; Haller et al., 2004). In the current experiment, WIN-
only treatment did not affect any of the measures.  
Food preference 
 
MDMA reduced intake of pellets, which is congruent with previous studies demonstrating that 
MDMA consumption reduces food intake and appetite in humans (Vollenweider et al., 1998; 
Kirkpatrick et al., 2011) and animals (Frith et al., 1987; Jean et al., 2007). Co-administration of WIN 
does not seem to have an effect on MDMA-induced hypophagia, as MDMA+WIN treated animals 
consumed even less than the MDMA group (means of total food intake: 2.7 vs. 4.5 grams), but this 
difference was not statistically significant. Food intake is a process mediated by stimulation of 5-HT 
receptors (Lam et al., 2010; Merroun et al., 2009). Although i.c.v. administration of WIN has been 
shown to decrease extracellular 5-HT and 5-HIAA in hypothalamic brain areas (Merroun et al., 
2009), this effect seems to be overruled by the strong MDMA-induced increase of 5-HT release 
and the associated reduction in food intake (Lam et al., 2010).  
WIN-treated animals did not differ from the vehicle-treated group in terms of food consumption. 
This result was somewhat unexpected since previous studies demonstrated an increase in food 
intake following THC or WIN administration compared to vehicle groups (Kirkham, 2005). For 
example, i.p. administration of WIN at doses of  0.5, 1 and 2mg/kg caused a significant increase in 
food intake from 1 hour - 6 hours after injection (Merroun et al., 2009). However, Merroun et al. 
(2009) did not find significant differences when comparing the non-cumulative amounts of food 
intake between vehicle- and WIN- (1 or 2mg/kg) treated animals. As with activity levels and body 
temperature, activation of CB1/2 receptors tends to evoke dose-dependent biphasic responses. 
WIN at doses of 1 and 2mg/kg promotes hyperphagia, whereas administration of a higher dose 
(5mg/kg) significantly inhibited food intake in partially satiated rats (Merroun et al., 2009). Drews et 
al. (2005) even found a significant reduction in the amount of pellets consumed by animals treated 
with 1.8mg/kg WIN. If orexigenic effects of the CB receptor agonist appear subsequent to maximal 
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blood concentration levels, hyperphagia may have been evoked only partially in the current study 
as testing took place 10 minutes after administration.  
 
Conclusion  
 
MDMA led to decreased choices of the HR choice in an effort-based decision making task. 
Furthermore, previously well-documented increases in activity and body temperature as well as 
decreased food intake were replicated. Overall, our behavioural tests do not support a modulatory 
role of WIN regarding MDMA-induced acute effects. Apart from an augmenting effect on body 
temperature, WIN administration alone did not yield effects distinct from vehicle treatment. 
Although there was a wash-out period of seven days between each test, additive or habituation 
effects cannot be completely ruled out. Future studies could vary the administration schedule and 
doses. In the current study, we used doses which in other animal studies have been shown to be 
behaviourally relevant (Drews et al., 2005; Young et al., 2005). However, since the dosage used in 
these experiments was relatively high, a lower dose of MDMA could reveal a putative potentiating 
effect of WIN. Many MDMA users consume cannabis concomitantly to enhance positive sensations 
or some time after MDMA consumption to alleviate adverse effects of the “come-down” (Winstock 
et al., 2001; Schulz, 2011). The neurobiological mechanisms underlying behavioural effects of 
MDMA, as well as co-consumption of cannabis, remain somewhat unclear as a complex interplay 
between 5-HT and DA release as well as activation of different 5-HT subtypes must be considered. 
Administration of specific CB1 agonists and manipulation of certain 5-HT receptors, and/or 
verification of DA and 5-HT-transmitter levels in brain areas known to be involved in behavioural 
responses, could further elucidate underlying pharmacological mechanisms. From these 
experimental tests in rats, we conclude that acute co-administration of a CB agonist does not 
substantially attenuate the MDMA-induced behavioural effects. 
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Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during 
puberty or adulthood reverses 3,4-methylenedioxymetamphetamine (MDMA)-
induced deficits in recognition memory but not in effort-based decision making 
 
Sybille Schulz, Thorsten Becker, Ulrich Nagel, Andreas von Ameln-Mayerhofer , Michael Koch 
 
Abstract 
 
Cannabis and 3,4-methylenedioxymetamphetamine (MDMA, “ecstasy”) are the most frequently 
combined illegal drugs among young adults in western societies. This study examined the effects 
of chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 (WIN) and MDMA 
on working memory and effort-based decision making in rats. Treatment consisted of MDMA 
(7.5mg/kg), WIN (1.2mg/kg), a combination of these substances (MDMA+WIN) or vehicle over a 
period of 25 days during puberty (PD40-65) or adulthood (PD80-105). Ten days after the last 
treatment, WIN reversed MDMA-induced working memory deficits in the object recognition test in 
animals treated during adulthood or puberty, but had no influence on impairment of adult rats in the 
effort-based T-maze task. No differences were observed between groups of pubertally treated rats 
in the decision making tasks. During a subsequent acute drug challenge MDMA and MDMA+WIN 
decreased high reward choices in both age groups, indicating MDMA-induced cost-aversive 
choice. Differential long-term interactions on the neuronal level in the hippocampus and MDMA-
induced disturbances in cortico-limbic connections are suggested.  
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Introduction 
 
The illicit drug 3,4-methylenedioxymetamphetamine (MDMA, “ecstasy”) is consumed for its 
stimulant effects including euphoria, increased energy and sensory awareness. MDMA is a potent 
monoamine releaser which dose-dependently influences the neurotransmitters serotonin (5-HT), 
dopamine (DA), and noradrenaline (NA) and binds to and reverses the direction of their respective 
reuptake transporters. Chronic and/or heavy administration has been associated with dysfunction 
and presumable selective neurotoxicity of serotonergic neurons and depletion of 5-HT levels in a 
variety of brain regions in animals (Green et al., 2003; Hatzidimitriou et al., 1999; Baumann et al., 
2007; Mayerhofer et al., 2001). Decreased densities of cortical serotonin transporter (SERT) were 
found in current MDMA users, however 5-HT neurotoxicity is debated in humans (Reneman et al., 
2001; Thomasius et al., 2006; Cowan, 2007). Recreational use of MDMA has been shown to 
impair learning and memory, for example, reduced immediate and delayed word recall (Dumont et 
al., 2010), disturbed verbal and visuo-spatial memory retrieval (Kuypers and Ramaekers, 2007; 
Murphy et al., 2009) and working memory (Nulsen et al., 2010). In addition, deficits in decision 
making processes, for example, elevated impulsivity (Morgan et al., 2006) and impaired decision 
making cognition in a gambling task (Quednow et al., 2007) were found. Especially after chronic 
and heavy consumption, cognitive impairments are exacerbated (Croft et al., 2001; Gouzoulis-
Mayfrank et al., 2003), and still persist even after one year of abstinence (Reneman et al., 2001; 
Zakzanis and Young, 2001; Gouzoulis-Mayfrank and Daumann, 2006a).  
 
Although studies in laboratory animals confirm acute effects of MDMA administration such as 
increased locomotor activity (Green et al., 2003; Cole and Sumnall, 2003), body temperature 
(DeSouza et al., 1997; Docherty and Green, 2010), social interaction (Morley and McGregor, 2000) 
and appetite suppression (O'Shea et al., 1998), studies of long-term effects after chronic 
administration in models of cognitive ability, such as memory tasks or more complex decision 
making are scarce. For example, Meyer et al. (2008) found deficits in an object recognition 
memory test in adult rats after intermittent exposure during adolescence. Three times 3 or 6mg/kg 
still impaired object recognition two weeks later (Rodsiri et al., 2011), and one week after a period 
of self-administration, object recognition memory was impaired, but recovered after 70 drug-free 
days (Schenk et al., 2011). A common form of decision making are cost-benefit choices, in which 
an individual needs to evaluate different options (involving costs) in terms of their outcome value 
(benefits) and weigh them against each other. The medial frontal cortex, specifically the anterior 
cingulate cortex (ACC), and interactions between prefrontal and sub-cortical brain structures are 
crucially involved in this form of decision making (Walton et al., 2002; Schweimer and Hauber, 
2006; Floresco and Ghods-Sharifi, 2007). However, effects of MDMA on effort-based decision 
making have not been examined. 
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The majority of ecstasy users also consume other drugs, and cannabis is the most frequently 
consumed and combined illegal drug. Approximately 95% of MDMA users report taking cannabis 
concomitantly (Gouzoulis-Mayfrank and Daumann, 2006b; Wu et al., 2009; Grov et al., 2009), 
mostly for its relaxant properties, thereby counteracting dysphoric symptoms of the “come down” 
from MDMA (Boys et al., 2001; Winstock et al., 2001).  Delta9-tetrahydrocannabinol (THC), the 
main psychoactive compound of cannabis, acts on endogenous cannabinoid type1 (CB1) and 
cannabinoid type2 (CB2) receptors. CB receptors play a role in the regulation of a variety of 
physiological processes such as body temperature, food intake, heart rate and locomotion (Elphick 
and Egertova, 2001; Ameri, 1999; Iversen, 2003). Stimulation of CB1 receptors generally inhibits 
neurotransmitter release. Human studies controlling for polydrug use, either via statistical means or 
arbitrary cut off criteria for cannabis use, reveal contradictory results. Some conclude that most 
cognitive and neurological effects cannot be allocated to long-term ecstasy use only, and may be 
in part due to concomitant consumption of cannabis (Lamers et al., 2006; Croft et al., 2001), or 
other drugs (Hanson et al., 2008). On the other hand, some studies comparing ecstasy and 
ecstasy+cannabis users with non-users suggest cognitive deficits to be attributable to ecstasy 
(Schilt et al., 2008), or found that participants using both drugs perform worse than ecstasy-only 
users on a range of learning and memory tasks (Fisk et al., 2006). In polydrug users, ecstasy use 
has been dose-dependently associated with impairments in executive control and decision making 
functions (Morgan et al., 2006), which is in line with predominantly cortically altered 5-HT 
transmission, and reported problems with long-term memory (Murphy et al., 2009). Deficits in 
short-term and prospective memory tasks are more robustly attributed to cannabis consumption 
(Solowij and Battisti, 2008), which supports the notion of long-lasting effects of stimulation of 
inhibitory CB1 receptors abundant in the hippocampus (Kano et al., 2009). Research in animals 
examining co-administration of MDMA and cannabinoid agents debates whether there are additive, 
interactive or regulatory effects on physiological, behavioural, and neurochemical measures. In 
rats, acute low and moderate doses of THC and MDMA disrupted performance in a working 
memory task (Young et al., 2005), whereas the CB1 antagonist AM251 ameliorated deficits in 
object recognition during withdrawal from MDMA (Nawata et al., 2010). Co-administration of either 
THC or the CB1 agonist CP55,940 reversed MDMA-induced hyperthermia and hyperactivity and 
prevented decreases in 5-HT concentration in hippocampus, amygdala, and prefrontal cortex 
(Morley et al., 2004). In CB1 knock-out mice, acute effects of MDMA (hyperthermia, increased 
locomotion, anxiety) were lower or absent compared to wild-type animals, indicating CB1 receptor 
involvement in these basic physiological processes (Tourino et al., 2008). Research examining 
long-lasting effects on behaviour after chronic co-consumption is scarce (Schulz, 2011). One 
recent study demonstrated that chronic co-administration of THC (5mg/kg, once a day) during 
adolescence counteracted MDMA (2 x 10mg/kg, every 5th day)-induced decreases in exploratory 
behaviour as well as reductions of 5-HT and serotonin transporter (SERT) levels in frontal, parietal 
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cortex and striatum, but not in the hippocampus. THC did not affect the loss of body weight (Shen 
et al., 2011). 
 
Apart from co-consumption of other drugs, age is another aspect of vulnerability to long-term 
effects of substance abuse. Most MDMA and cannabis users are young adults or adolescents 
(EMCDDA, 2009; Wu et al., 2009), and drugs may have differential effects on adolescent brain 
function (Spear, 2000). Specifically, impairments in left hippocampus functioning were associated 
with memory deficits in adolescent MDMA users, suggesting an increased vulnerability to cognitive 
and neuronal impairments during this age period (Jacobsen et al., 2004). Dauman et al. (2005) 
found similar diminished hippocampus activity in adult MDMA polydrug users, albeit without 
decreased memory performance. Whether this discrepancy is due to age-related changes or 
possibly compensating effects of other drugs remains speculative. Rodent experiments have 
shown an influence of early exposure to MDMA on behaviour and serotonergic functioning. In 
pubertal female rats, repeated exposure to 3 and 10mg/kg MDMA lead to a transient increase in 
locomotor activity, whereas stimulatory effects in adult animals were continuous (Wiley et al., 
2011). Juvenile rats (postnatal day (PD) 25-30) showed a moderate vulnerability to MDMA-induced 
decreases in 5-HT binding, whereas adult rats (PD90), where maximally susceptible (Kelly et al., 
2002). Furthermore, exposure to cannabinoid agents during adolescence can lead to persisting 
changes in brain functioning as well as behavioural and cognitive performance (Rubino and 
Parolaro, 2008; Wegener and Koch, 2009b). For example, chronic treatment with the CB1 agonist 
WIN55,212-2 during adolescence, but not adulthood, lead to deficits in recognition memory and 
impairments in a progressive ratio task (Schneider and Koch, 2003). Long-term effects of chronic 
MDMA-administration, as well as of the combination of MDMA and a CB1 receptor agonist, during 
adolescence and adulthood on memory performance and complex decision making have not been 
investigated.  
 
This study addresses two questions: First, how does chronic MDMA administration affect working 
memory and effort-based decision making, and does co-administration of WIN55,212-2 alter these 
effects? Second, are these effects age-dependent, i.e. different when administered during puberty 
or adulthood? 
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Materials & Methods 
Animals 
 
Forty-eight adult naive male Wistar rats (Harlan, Borchen, Germany) weighing 230-300 grams 
upon start of the experiment were used. Upon arrival, animals were allowed to habituate for 4-5 
days in a vivarium under standardized conditions (4-6 animals per Makrolon type IV cage; tap 
water ad libitum; 12:12 hour light/dark circle, lights on at 7am; temperature 22+/- 2°C) and were 
handled regularly. In addition, 48 pubertal rats were taken from the in-house breeding facility. On 
postnatal day (PD) 21 they were weaned and afterwards housed under the same conditions as the 
adult rats. During the habituation and handling period, standard lab chow was available ad lib for 
all animals. For adult rats, controlled feeding (12g/animal/day) started two days before the first 
training session and for pubertal rats ten days after the last drug treatment. All animal experiments 
were conducted in accordance with the principles of animal care and the international laws on 
animal experiments (Directive 2010/63/EU) and were approved by the local authorities. 
 
Drugs 
 
All drugs were prepared freshly every third injection day before administration and injected in a 
volume of 1ml/kg. WIN55,212-2 (SIGMA-Aldrich, Steinheim, Germany) was dissolved in 2% 
Tween®80 (Serva, Heidelberg, Germany) and 98% NaCl solution (0.9% NaCl, Fresenius Kabi 
GmbH, Bad Homburg, Germany) and injected at a dose of 1.2mg/kg, intraperitoneally (i.p.). (±)3,4-
methylenedioxymetamphetamine hydrochloride (synthesized in the Institute of Inorganic 
Chemistry, Prof. Nagel, University of Tübingen, Germany. Identity and chemical purity was verified) 
was dissolved in phosphate buffered saline (PBS), and injected at a dose of 7.5mg/kg, 
subcutaneously (s.c.). PBS injection (1ml/kg) served as vehicle control. 
 
Treatment 
 
Adult as well as pubertal rats were divided into four groups, respectively (n=12): MDMA group 
(receiving only MDMA injections), WIN group (only WIN injections), MDMA+WIN group (receiving 
both MDMA and WIN injections) and the control group (receiving PBS injections). Half of the 
control group animals received two vehicle injections to control for any effect two injections might 
have. There was no apparent or statistical effect in any of the measures, therefore, all 12 animals 
receiving PBS injections constituted the control group. The injection schedule was pseudo 
randomized over a period of 25 days, with adult rats receiving treatment from approximately PD80-
105 (three weeks after arrival), and pubertal rats from PD40-65. Animals received no treatment on 
10 days, one treatment per day on 10 days, and two treatments per day on 5 days, summing up to 
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a total of 20 injections. On days with two treatments, these were done at least 4 hours apart from 
each other.  
 
Behavioural tests 
 
Behavioural testing was conducted in a between subjects design. Adult as well as pubertal rats 
underwent the same training and testing procedure. Six animals per treatment group were pre-
trained in the effort-based or delay-based decision making task for approximately 14 days prior to 
drug treatment and tested two weeks after the last injection. All remaining behavioural tests were 
conducted after long-term treatment with n=12.  
Object recognition test 
 
Based on recognition of a previously explored object, the object recognition task allows 
measurement of working memory without training procedures (Ennaceur and Delacour, 1988). Ten 
days after the last treatment, animals (n=12) were singly placed into a Makrolon type II cage and 
allowed to habituate to the environment for 30 minutes. On the following day, they explored the first 
object (object1) for 5 minutes. The time during which the animal was actively exploring the object 
(sniffing, licking, gnawing, pushing/pulling, handling) was recorded. After 25 minutes, a novel 
object (object2) was placed into the Makrolon type II cage together with object1 (now object 1B) in 
order to directly compare exploration times. For half of the animals, the first object was a small 
beaker and the second object a closing tap of a water dispenser, for the other half the order of 
objects was reversed. For the pubertally treated rats, the same testing procedure was repeated 
four weeks after the last treatment in order to monitor long-term effects as well as to compare their 
performance at the same age as adult rats were tested at. 
Effort-based decision making  
 
This task allows monitoring of effort-related decision making choice behaviour, i.e., how much 
effort the animal is willing to exert to obtain a larger reward. At the end of the arms of the T-maze 
(measurements of each arm: 60 cm x 15 cm x 30 cm (L x W x H)) either two or four pellets (Bio-
Serv©, UK Dustless Precision Pellets©, 45mg) were placed in a metal food well. While the arm 
containing two pellets (low reward arm, LR) was freely accessible for the rats, a 30 cm barrier 
made of wire mesh was placed in the arm containing four pellets (high reward arm, HR). The HR 
was the right side T-maze arm for half of the animals, and left side for the other half. Pre-training 
sessions took place once a day for an average of 14 days. All animals (n=6) were habituated to the 
apparatus as well as to increasing heights of the barrier, and were trained until all animals reached 
a mean baseline level of ≥ 80% choice of HR for three consecutive days. Some animals reached 
baseline level prior to 14 days; they remained included in the group training. Inter-trial interval (ITI) 
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was one minute (for further detail on apparatus and training method see (Walton et al., 2002), 
adapted from the original study by Salamone (1994)). Post-treatment sessions started 12 days 
after the last injection day. The first session consisted of 10 forced trials only, i.e. animals were 
hindered entering the HR or LR arm in a pseudo randomized order by one grey sliding door in the 
choice area. During 10 following training sessions, animals could freely choose which reward arm 
they entered. On post-training day 11, animals absolved the testing under acute substance 
influence as a drug challenge was conducted, during which rats received the same substances 
they had been treated with chronically.  
Delay-based decision making 
 
This task allows examining one aspect of impulsivity, namely the ability to tolerate delays of 
reward. It was conducted in the same T-maze apparatus as the effort-based decision task. 
Removable, non-transparent guillotine doors were placed at the entry of the starting way, at the 
choice area, and at the entry of each goal area. The food wells in the goal areas contained either 2 
pellets (low reward arm, LR, no delay), or 10 pellets (high reward arm, HR, 10 seconds delay). Pre-
training consisted of habituation of the animals (n=6) to the apparatus, sliding doors, as well as to 
increasing waiting times for the HR and training until as a group they reached baseline level of 
≥70% choice of HR for three consecutive days (for further details on training and testing procedure 
see for example, (Hadamitzky et al., 2009; Bizot et al., 1999)). Post-treatment training and 
challenge followed the same procedure as in the effort-based task. 
Locomotion 
 
Animals (n=12) were gently placed into infrared beam-controlled acrylic glass chambers (ActiMot-
system; TSE, Bad Homburg, size: 44.7 cm x 44.7 cm x 44 cm) measuring horizontal (locomotion) 
and vertical (rearings) activity. This test was performed on day 11 days after cessation of the drug 
treatment. Locomotion and exploratory behaviour was automatically recorded by a PC (ActiMot 
Software; TSE, Bad Homburg) for 35 minutes and stored as aggregated data in seven 5-minute 
intervals. Parameters analysed were number of rearings, total activity (%), and time spent in centre 
(%). This test was repeated four weeks later. 
 
Body weight 
 
The body weight of the animals was measured using a laboratory scale on each of the 15 
treatment days before injection as well as on the substance challenge day before the T-maze tests. 
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Statistical analysis 
 
For data analysis, analyses of variance (ANOVAs) were conducted with SigmaStat2.03 for 
Windows (SPSS Inc., Chicago, IL, USA), followed by post hoc Tukey tests for pairwise multiple 
comparisons. For all measurements, p<0.05 was considered significant. 
Results  
 
Object recognition test 
 
Rats treated with MDMA during adulthood explored object1, object1B and object2 for a similar 
amount of time, an effect which was not apparent for MDMA+WIN, WIN, or vehicle-treated 
animals. ANOVA confirmed that there was a significant difference in the time spent exploring the 
objects for the control group [F(2,22)=10.30, p<0.001]), the WIN group [F(2,22)=8.61, p=0.002], 
and the MDMA+WIN group [F(2,22)=10.17,p=0.006]. Post-hoc test revealed a decrease in the time 
spent exploring the first object (object1) when it was presented for the second time (object1B), 
compared to the first presentation of the same object (p=0.002 to p=0.003) as well as to the 
presentation of the second object (object2, p=0.002 to p=0.009). There was no statistical difference 
in exploration times of the objects within the MDMA group (p=0.398, Fig.1a). Ten days after the 
last treatment, exploration times of object1, object1B and object2 did not differ for rats treated with 
MDMA during puberty. This effect was not apparent for MDMA+WIN, WIN, or vehicle-treated 
animals. ANOVA revealed that there was a trend towards a significant difference between the 
exploration times of the objects for the control group [F(2,22)=2.11, p=0.14], as well as significant 
differences in exploration times for the WIN [F(2,22)=20.17, p<0.001] as well as MDMA+WIN-
treated groups [F(2,22)=8.07, p=0.002]. Post-hoc Tukey test showed that animals spent 
significantly more time exploring object1 compared to object1B (WIN: p<0.001, MDMA+WIN: 
p=0.002). Animals treated with MDMA showed no difference in exploring the objects [F(2,20)=0.71, 
p=0.50] (Fig.1b). Four weeks later, the between group differences persisted, in that all but the 
MDMA-treated group showed significant differences between the objects (control: [F(2,22)=3.87, 
p=0.036], WIN: [F(2,22)=7.93, p=0.003], MDMA+WIN: [F(2,22)=5.60, p=0.011]) In particular, 
animals explored object1 longer than object1B (control: p=0.031, WIN: p=0.002, MDMA+WIN: 
p=0.010) (Fig.1c). 
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Fig.1: Object recognition test. Mean time (+SEM) exploring object1, object1B, and object2 during the 
object recognition test. Rats treated during adulthood and puberty were tested 10 days after the last 
treatment (a- upper panel and b- lower panel, respectively), pubertally treated rats were re-tested again 4 
weeks later (c). All symbols p<0.05. * denotes significant differences in exploration times between object1 
and object1B, # denotes significant differences between object1B and object2. 
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Effort-based decision making 
 
MDMA+WIN as well as MDMA-treated adult rats took longer to resume baseline level (>80% HR 
arm choices) than WIN and vehicle-treated rats, and chose the HR arm less often during the acute 
challenge. ANOVA confirmed significant effects for the factors treatment [F(3,217)=12.94, p<0.001] 
and post-training day [F(10,217), p<0.001]. Post-hoc test revealed that control- and WIN-treated 
animals chose the HR significantly more often than both MDMA- and MDMA+WIN-treated rats 
(p<0.001). Overall, animals chose the HR significantly less often on post-training day 11 (challenge 
day) compared to days 6-8 (p=0.011, p=0.029, p=0.031, respectively). MDMA-treated animals 
chose the HR significantly more often on post training days 5 and 6 compared to day 1 (p=0.038, 
p=0.011, respectively). MDMA+WIN-treated animals chose the HR significantly less often on day 
11 compared to days 8-10 (p=0.026 and p=0.037). No treatment x day interaction was apparent for 
control and WIN-treated animals. On the first post-training day, both control and WIN-treated 
animals chose the HR significantly more often than MDMA-treated animals (p=0.033, p=0.011, 
respectively), whereas on the third day, control and WIN-treated animals chose the HR more often 
than MDMA+WIN-treated animals (p=0.024, p=0.017, respectively). On the second post-training 
day, WIN animals chose the HR more often compared to the MDMA+WIN group (p=0.033). On 
post-training day 11 (challenge day) control group animals preferred the HR arm compared to the 
MDMA+WIN group (p=0.022), and there was a trend toward significance for the difference of HR 
choice between the WIN and the MDMA+WIN group (p=0.075) (Fig.2a).  
 
Drug treatment during puberty did not influence resumption of baseline level for any group, 
however during the acute challenge, MDMA administration led to less HR arm choices. ANOVA 
showed a significant effect for the factor post-training day [F(10,209)=2.66, p=0.005] and a strong 
trend toward significance for treatment [F(3,209)=2.49, p=0.061]. Post-hoc Tukey test revealed a 
higher percentage of overall HR choices on day 10 compared to day 2 (p=0.033). Within the 
MDMA-treated group a trend towards a significant difference (p=0.091) was revealed when 
comparing day 10 to day 11 (challenge day). Control animals chose the HR arm significantly more 
often than MDMA+WIN-treated animals on post-training day 1 and more often than MDMA-treated 
animals on day 11 (p=0.030, p=0.013, respectively) (Fig.2b). 
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Fig.2: Post-training phase of the effort-based decision making task and drug challenge. Percent 
choice of the high reward (HR) arm (%)(+/-SEM) during ten days of post-training (day 1=13th  day after last 
treatment) and challenge day (day 11) after chronic treatment (n=6) for a rats treated during adulthood. # 
denotes significant differences within the MDMA+WIN group compared to training days 8-10, & denotes 
significant differences between MDMA+WIN group and control group, $ denotes differences within the 
MDMA-group compared to training days 5 and 6, * denotes significant difference between MDMA and control 
animals. b pubertally treated rats, where * denotes significant difference between MDMA and control groups, 
&
 denotes significant differences between MDMA+WIN group and control groups. All symbols p<0.05. 
 
Delay-based decision making 
 
No effects for substance or post-training day were found for rats treated during adulthood.  
Data from rats treated during puberty showed significant effects for the factors substance 
[F(3,220)=4.04, p=0.008] as well as post-training day [F(10,220)=2.23,p=0.017]. Post-hoc test 
revealed overall less HR choices for animals treated with WIN compared to MDMA+WIN (p=0.027) 
and MDMA (p=0.035) treatment. Furthermore, animals chose the HR arm significantly more often 
on days 9 and 10 compared to day 1 (p=0.022, p=0.036, respectively). No further interaction was 
found (data not shown). 
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Locomotion 
 
Chronic drug treatment during adulthood did not influence horizontal or vertical locomotor activity 
11 or 39 days after the last administration. A two way repeated measures ANOVA confirmed no 
effect for treatment or time point of measurement for the parameters activity (seconds), distance 
(meters), or number of rearings (all p>0.78). A significant treatment effect was found when 
comparing the time spent in the centre of the open field [F(3,88),p=0.036], and post-hoc test 
revealed that WIN treated rats spent significantly less time in the centre compared to MDMA+WIN-
treated rats (p=0.038), as well as a trend towards a significant difference between WIN- and 
MDMA-treated rats (p=0.081) (Table 1). 
Chronic drug treatment during puberty did not influence horizontal activity or anxiety-like 
exploration 11 or 39 days after the last administration, however, the number of rearings increased 
with increasing age. ANOVA confirmed no significant effect for the factor treatment or time point of 
measurement for the parameters activity (secs) and time spent in the centre (%) (all p>0.05). 
There was a significant effect of time point of measurement for the parameter rearings 
[F(1,43)=19.63, p<0.001), and post-hoc tests revealed all treatment groups reared more often 
during the second measurement (four weeks following the first). This difference was significant for 
MDMA-, MDMA+WIN-treated as well as control animals (p=0.025, p=0.022, p=0.034, respectively; 
WIN: p=0.055). In terms of distance (meters), the time point of measurement showed a significant 
effect [F(1,43)=8.53,p=0.006], with post-hoc test revealing control animals running more meters 
during the second measurement (p=0.032), and WIN treated animals showing a strong trend 
towards significance (p=0.070) (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study 2 
 
 
64 
 
Table1: Locomotor activity and exploratory behaviour. Mean activity, number of rearings, distance 
travelled and time spent in the centre (SEM) measured on two time points (11 and 39 days after the last 
treatment) is shown for animals treated during adulthood or puberty. #denotes a significant difference within 
treatment groups between time points of measurement, *denotes difference compared to MDMA+WIN-
treated animals. All symbols indicate p<0.05. 
 
Body weight 
 
For rats treated during adulthood, significant effects were found for injection day [F(15,45)=26.55, 
p<0.001] as well as for treatment [F(3,45)=8.37, p<0.001]. Post-hoc tests revealed a significant 
decrease in weight between day 2 and day 14 (p=0.032 to p<0.001) as well as increased weight on 
day 16 (challenge day) compared to days 3-15 (p=0.014 to p<0.001). Furthermore, MDMA-, WIN-
treated and control animals weighed significantly more than MDMA+WIN-treated rats (all p<0.001) 
(data not shown). 
All pubertal animals gained weight during the course of treatment; however MDMA as well as 
MDMA+WIN treated rats gained less than the WIN and vehicle groups. ANOVA revealed 
significant effects for treatment [F(3,655)=37.13, p<0.001] as well as for injection day 
[F(15,655)=294.58, p<0.001]. Post-hoc test showed control and WIN-treated animals weighing 
significantly more than MDMA+WIN- and MDMA-treated rats (all p<0.001). Specifically, WIN-
treated animals weighted significantly more than MDMA and MDMA+WIN-treated animals on 
injection days 8 to 15 (p=0.015 to p<0.001), and control animals weighted significantly more than 
MDMA+WIN animals on day 7, 9-11, 14 and 15, and more than MDMA-treated animals on days 9 
and 13-15 (p=0.049 to p=0.005) (Fig.3). No significant weight difference was observed on the 
challenge day. 
Treatment during 
adulthood Activity (secs) 
Number of 
rearings Distance (meter) Time in centre (%) 
Vehicle 63,70 (5,85) 
64,42 
(6,08) 
17,54 
(2,48) 
19,42 
(2,33) 
22,05 
(2,43) 
23,00 
(2,68) 
6,27 
(1,47) 
3,38 
(0,74) 
MDMA 66,20 (5,95) 
62,09 
(7,33) 
18,01 
(3,04) 
15,98 
(2,82) 
23,37 
(2,54) 
22,86 
(2,59) 
4,84 
(1,64) 
2,94 
(0,81) 
WIN 61,79 (9,20) 
61,58 
(8,40) 
16,27 
(3,36) 
17,73 
(3,69) 
22,73 
(3,96) 
22,09 
(3,63) 
7,10 
(2,97) 
 8,40* 
(3,02) 
MDMA+WIN 58,29 (5,59) 
59,17 
(6,17) 
16,35 
(3,07) 
17,71 
(3,64) 
21,18 
(2,83) 
20,71 
(2,94) 
3,58 
(1,45) 
2,80 
(0,55) 
Treatment during 
puberty 
        
Vehicle 60,58 (4,32) 
66,50 
(4,53) 
13,78 
(1,80) 
18,30# 
(1,77) 
20,97# 
(2,02) 
25,18 
(2,23) 
3,20 
(1,58) 
6,64 
(2,23) 
MDMA 50,73 (3,74) 
56,91 
(2,35) 
10,33 
(1,50) 
15,33# 
(1,20) 
17,86 
(2,17) 
18,30 
(0,31) 
1,95 
(0,85) 
4,07 
(1,95) 
WIN 62,33 (3,70) 
62,83 
(4,31) 
15,32 
(1,05) 
19,39 
(2,00) 
20,05 
(1,58) 
23,58 
(2,36) 
5,12 
(1,98) 
4,10 
(0,97) 
MDMA+WIN 61,58 (4,54) 
65,83 
(3,4-6) 
13,25 
(1,85) 
18,14#    
(1,45) 
20,52 
(1,92) 
23,57 
(1,35) 
2,25 
(0,58) 
4,05 
(0,72) 
Time point of 
measurement 11 days 39 days 11 days 39 days  11 days 39 days 11 days 39 days  
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Fig.3: Weight change of pubertal animals on injection and challenge days. Effect of chronic treatment 
with WIN, MDMA, MDMA+WIN, or vehicle (n=12) on weight gain of pubertal rats fed ad libitum. Mean body 
weight (grams) (+/-SEM) are depicted for fifteen injection days and the challenge day (16). # denotes 
significant difference between WIN- versus MDMA- and MDMA+WIN-treated animals, * and & denote 
significant difference of control versus MDMA and MDMA+WIN groups, respectively. All symbols indicate 
p<0.05. 
 
Discussion 
 
In rats chronically treated with MDMA, memory deficits in working memory (object recognition test) 
as well as in long-term memory (re-learning of the effort-based decision making task) were 
apparent. This is in line with human and animal studies observing deficits in memory after long-
term administration. Abnormal functioning of the left hippocampus during a working memory task 
was found in adolescent MDMA users (Jacobsen et al., 2004), and impairments in working 
memory in adult rats intermittently treated with MDMA during puberty (Meyer et al., 2008). In 
contrast to studies proposing increased vulnerability of adolescents to the effects of cannabinoids 
(Schneider and Koch, 2003; Rubino and Parolaro, 2008), long-term CB1 receptor stimulation did 
not influence performance in the object recognition test or the more complex effort-related decision 
making, as WIN-treated animals behaved similar to control rats. The most interesting result here is 
the reversal of the MDMA-induced deficit in object recognition for adult as well as pubertal treated 
rats by co-administration of WIN. The fact that WIN attenuated MDMA-induced deficits in the 
memory task but not in the effort-based decision making task points to a long-term neurobiological 
interaction of these substances within brain regions involved in short-term memory, rather than in 
the execution of the more complex decision making tasks. A likely candidate for the location of 
interactive effects on working memory is the hippocampus, which has a high vulnerability to toxic 
events, including presumable MDMA-induced deterioration of 5-HT nerve fibres (Hatzidimitriou et 
al., 1999; Green et al., 2003). However, Rodsiri (2011) found impairments of object recognition 
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memory without reduction of 5-HT levels in frontal cortical or hippocampus areas two weeks after 3 
or 6mg/kg MDMA binges, indicating neurotoxicity-independent mechanisms for long-lasting 
memory deficits. This is in line with studies indicating that MDMA-induced deficits in recognition 
memory are not due to serotonergic alterations (Nawata et al., 2010; Piper and Meyer, 2004). 
Nevertheless, 3, 6, and 15mg/kg MDMA increased extracellular concentrations of 5-HT in the 
hippocampus one hour after acute administration (Rodsiri et al., 2011; Mechan et al., 2002). 
Repeated MDMA administration enhanced long-term potentiation (LTP) (Morini et al., 2011), 
probably due to postsynaptic DA- as well as presynaptic 5-HT2 receptors (Rozas et al., 2011). 
Importantly, the hippocampus is an area expressing CB1 receptors in high levels (Pertwee et al., 
2010; Herkenham et al., 1991), and might therefore be particularly sensitive to cellular changes 
due to chronic MDMA administration and CB1 agonist treatment. Specifically, in contrast to MDMA, 
CB1 receptor agents impair LTP (Schlicker and Kathmann, 2001; Collins et al., 1995), thus 
possibly preventing MDMA-induced long-term alterations on a cellular level. Another mechanism 
could be neuroprotection by cannabinoids. Although chronic cannabinoid administration has 
previously been shown to induce deficits in learning and memory tasks as well as morphological 
changes in the brain, in vitro studies demonstrate the protective effects of cannabinoid agents, 
specifically WIN, against excitotoxicity via a decrease of glutamate release (Shen and Thayer, 
1998). In line with our results, Shen (2011) found a reduction of MDMA-related behavioural 
changes and attenuation of reduced 5-HT levels and SERT binding after chronic co-administration 
of THC. Other studies found a deficit in working memory when MDMA and THC were co-
administered (Young et al., 2005), or a similar ameliorating effect on recognition memory during 
MDMA-withdrawal when a CB1 receptor antagonist was co-administered (Nawata et al., 2010). 
However, these studies investigated memory impairment after acute, rather than chronic 
administration, or used mice in which MDMA predominantly affects the DA system, rather than rats 
(O'Shea et al., 2001; O'Shea et al., 1998). In MDMA-treated mice, THC has been shown to reduce 
DA terminal loss, presumably due to CB1 receptor activation (Tourino et al., 2010), pointing to a 
neuroprotective mechanism of CB1 agonists. Since the current study did not assess 
neurotransmitter levels, this interpretation is based on behavioural interactions only. Our results 
nevertheless indicate strong regulatory effects of chronic co-treatment with a cannabinoid agonist 
during puberty as well as adulthood on long-lasting MDMA-induced working memory deficits, 
supporting the notion of WIN having long-term protective effects on neurobiological changes in the 
hippocampus evoked by MDMA administration.  
 
Deficits in effort-based decision making were observed for both MDMA- and MDMA+WIN-treated 
adult rats during the first five days of post-training. Chronic MDMA-treatment seems to have an 
effect on memory retrieval, rather than inability to complete the task, and this effect is more 
pronounced if treated during adult age. Pubertally treated animals needed similar training time to 
resume to near-baseline levels irrespective of treatment, whereas within the adult group, MDMA as 
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well as MDMA+WIN treated animals took longer to re-learn compared to control and WIN-treated 
animals. Repeatedly administered MDMA has been shown to enhance LTP, a cellular mechanism 
crucial to the formation of long-term memory (Peng et al., 2011). Brain areas implicated in this 
process, as well as in retrieval of previously learned information are the hippocampus and its 
connections to cortical areas, specifically frontal, anterior cingulate and temporal cortex (Bontempi 
et al., 1999), which exhibit only moderate density of CB1 receptors (Pertwee, 1997). Therefore, 
CB1 receptor activation might be insufficient to attenuate damage to prefrontal areas due to 
chronic MDMA-administration during adulthood. In contrast, frontal areas responsible for storage 
and retrieval of long-term memory and effort-based decision making are among the last to mature 
(Sowell et al., 1999). Therefore, if neuronal transmission is disturbed by MDMA-administration 
during puberty, compensative mechanisms might take effect, whereas damage to adult rats may 
be irreversible. In line with this, adult rats generally are even more vulnerable to MDMA-induced 
long-term depletion of 5-HT (Piper, 2007). Acute effects of MDMA, WIN and their combination on 
decision making are discussed elsewhere (Schulz et al., submitted). However, when challenged 
with the respective substances, MDMA or MDMA+WIN-treated animals in both age groups chose 
the HR arm less often than WIN and control animals, indicating effort-aversive decision making 
upon acute MDMA administration irrespective of WIN co-administration and previously learned 
strategies. In another study, acute MDMA-administration in adult rats induced increases in 
reference memory errors, i.e., impairments in re-using the strategy from a previous trial to solve a 
task (Kay et al., 2010). Furthermore, the well described MDMA-induced 5-HT and DA release 
might influence fronto-striatal circuitry (Floresco et al., 2008) or nucleus accumbens function 
(Kurniawan et al., 2011). However, the specific role of these neurochemical effects in regulating 
effort-based choice remains elusive. 
 
No effects of chronic treatment with either substance could be observed for the delay- based task, 
an animal model of impulse control action. Rats pubertally treated with WIN showed an overall 
decrease of HR choices compared to MDMA as well as MDMA+WIN-treated animals, however no 
differences to the control group were found. This task is generally more difficult to acquire than the 
effort-based task, as observed during pre-training. All animals, including controls, took longer or 
failed to recover baseline levels after treatment, although the number of overall HR choices 
increased toward the last two post-training days. Furthermore, no differences were found during an 
acute challenge for any age or treatment group. In line with this, Saadat (2006) found no long-term 
changes in behavioural inhibition after a high dose administration of MDMA, despite significant 
depletion of cortical 5-HT. The absence of an effect of chronic treatment on delay-based choice 
points to more pronounced MDMA-induced alterations in the medial prefrontal cortex, specifically, 
the ACC, involved in effort-based choices, compared to the orbitofrontal cortex, which has been 
shown to regulate delay-based decisions.  
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The drug effects on learning and memory are not due to impairments in locomotion, as there where 
no differences in terms of activity, rearings or distance travelled between the treatment groups. The 
increased time adult rats previously treated with MDMA or MDMA+WIN spent in the centre 
compared to WIN-treated rats probably reflects a slight decrease in exploration anxiety rather than 
an increase of anxiety in WIN-treated rats, as the latter did not differ from controls. The significantly 
increased number of rearings of all pubertally treated rats most likely reflects age-dependent, 
rather than treatment-related, differences (cf. animals treated during adulthood). Adding to the well-
established effect of hyperactivity after acute MDMA treatment (Green et al., 2003), and 
amelioration thereof by cannabinoid agents (Morley et al., 2004), our results indicate that chronic 
administration of MDMA does not result in long-term hyperactivity.  
 
With respect to body weight, adult MDMA animals kept on a restricted feeding regime weighed 
slightly more than controls and WIN-treated animals, probably because they were kept under 
restricted feeding conditions in one cage with MDMA+WIN animals, which had a reduced food 
intake, so that MDMA-treated rats were left with more available food. Results are clearer for 
pubertal animals which were fed ad libitum, where an anorexic effect of MDMA is apparent. 
Reduced food intake can influence food reward-based tasks such as delay- or effort-based 
choices; however, animals treated during puberty with MDMA or MDMA+WIN did not differ from 
their controls in these tasks. WIN-treatment did not ameliorate MDMA-induced decrease in weight 
change, indicating no additive or interactive effect of the substances on this physiological measure 
(see Shen at al, 2011). 
 
Conclusion 
 
Chronic WIN co-treatment during puberty or adulthood did not have additive or regulatory effects 
on MDMA-induced behavioural changes in locomotion or body weight. However, it resulted in long-
lasting recovery of MDMA-induced deficits in recognition memory, presumably by interaction of 
altered 5-HT neurotransmission and CB1 receptors in the hippocampus. MDMA-induced 
disturbances of decision making after chronic administration are not modulated by CB1 receptor 
agonism in adult rats.  
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Histological verification of the density of myelinated axons following chronic treatment with 
MDMA, WIN55,212-2, or their combination 
 
MDMA has been shown to be neurotoxic, and behavioural observations after chronic treatment in pubertal as 
well as adult animals point to neuronal changes at least in the hippocampus (see Study 2). On the other 
hand, cannabinoid agents are anti-oxidant and anti-inflammtory, and thus might be able to block or prevent 
cellular changes induced by MDMA-administration. Therefore, histological examination of the brains from the 
animals used in Study 2 was the logical subsequent step. As an indication of structural changes underlying 
treatment-induced behavioural changes, myelination density was examined in various brain areas. 
Myelination is an insulation sheath (formed by oligodendrocytes in the CNS) around axons which serves as 
an accelerator for signal transmission in the nervous system (Hartline and Colman, 2007). Many studies 
have demonstrated disturbed or degenerated myelination in patients suffering from psychiatric or 
inflammatory disorders, such as schizophrenia or multiple sclerosis (MS) (Emery, 2010; Bartzokis, 2012). 
Method: Gold-chloride staining 
From each treatment group (MDMA, WIN, MDMA+WIN and Vehicle), six rats were randomly chosen. 
Following transcardial perfusion (250 ml phosphate buffered saline followed by 500ml 4% paraformaldehyde 
in 0.1 PB), brains of the animals were removed and frozen at -17°C until they were cut on a cryostat (Jung 
CM 3000, Leica Instrument GmbH, Nussloch, Germany). Every sixth slice (40µm) was mounted onto a 
gelatinised glass slide and stained with 0,2% gold-chloride solution (AuCl4, Roth, Karlsruhe, Deutschland) 
for 1-3 hours. Staining was terminated upon articulated visibility of the hippocampus as red-brown structure. 
Slices were rinsed in aqua dest. and fixated in freshly prepared 2,5% Na-Thiosulfate solution for 5 minutes. 
After rinsing for 30 minutes under running tap water and aqua dest., slices were dehydrated in an ascending 
ethanol series (50, 70, 80, 96, 100%) and cover-slipped in Terpineol and Rotihistol. Myelination levels in 
different brain areas were microscopically analysed by an experimenter blind to the treatment conditions 
using image analysing software MetaMorph (Version 4.6, Universal Imaging Corp., Downington PA 19335, 
USA). In the digital image taken at hundredfold magnification, contrast was enhanced in order to enable the 
software to detect and label stained fibres. Within the area of interest (according to the rat brain atlas of 
Paxinos and Watson, 1998), myelination levels were calculated as % stained. 
Results 
Overall, MDMA+WIN treatment resulted in the lowest levels of myelination for both age groups in most 
analyzed areas. Brains of animals treated during adulthood showed decreased myelination after WIN 
treatment compared to vehicle and MDMA-treatment, whereas for the pubertally treated animals myelination 
levels after WIN treatment did not differ from vehicle or MDMA-treatment. Out of the 21 brain areas chosen 
to compare the density of myelination, one-way ANOVA revealed significant differences between treatment 
groups within seven regions. For rats treated during adulthood these include: Nucleus accumbens core 
[F(3,19)=4.56; p=0.014], nucleus accumbens shell [F(3,19)=6.16; p=0.004)], hippocampal areas CA3 
[F(3,19)=8.16; p=0.001] and CA1+2 [F(3,18)=3.45; p=0.039], as well as the dorsal [F(3,15)=3.39; p=0.046], medial 
[F(3,15)=6.87; p=0.004] and caudal [H=13.57; p=0.004] raphe nuclei. Pubertally treated rats showed 
differences within the basolateral amygdala [F(3,20)=11.23; p< 0.001], central amygdala [F(3,20)=6.48; 
p=0.003], hippocampal areas CA3 [F(3,18) =19.26; p<0.001] and CA1+2 [F(3,16) =5.10; p=0.012], as well as  
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dorsal [F(3,16)=3.73; p=0.033], medial [F(3,15)=4.57; p=0.018] and caudal [F(3,14)=11.10; p<0.001] raphe nuclei. 
Results of the post-hoc (Tukey) tests according to age group are shown in Fig.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10: Mean density of myelination (%) according to treatment and brain region for rats treated 
during a) puberty or  b) adulthood. Depicted are data for nine brain areas within which significant 
differences were found for either age group. Square brackets denote p<0.05 unless otherwise indicated. 
[Frontal brain areas (including the orbitofrontal and limbic cortex) were also examined, however data are 
omitted here because of very low amount of white matter and very similar (high signal-to-noise ratio) 
myelination levels irrespective of treatment group.] 
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Fig.11: Hippocampus CA 1+2 area. Representative photographs of adult brain slices (-2.56 mm relative to 
Bregma) after chronic Vehicle (a), MDMA (b), MDMA+WIN (c) or WIN (d) treatment. Scale bar = 100µm. 
 
Discussion 
 
Chronic MDMA+WIN treatment reduced myelination in all brain regions examined. This effect seems to be 
independent from age during treatment. WIN-treatment during adulthood decreased myelination levels to 
equal amounts than the combination MDMA+WIN. Thus, the cannabinoid receptor agonist seems to have a 
degenerating effect on white matter, at least in hippocampal areas and raphe nuclei of adult rat brains. This 
is in line with studies indicating that chronic, low doses of cannabinoids might be neurotoxic, whereas acute 
doses have neuroprotective effects (Sarne and Keren, 2004), and long-term alterations on the cellular level 
after chronic administration of cannabinoid receptor agonists (Wegener and Koch, 2009b). On the other 
hand, symptoms and disease progression of MS in animal models, and reduction of spasticity in human 
patients can be attenuated by cannabinoids (THC, canabidiol, WIN), presumably due to anti-inflammatory 
effects (de Lago et al., 2012; Sanchez and Garcia-Merino, 2012). However, whereas cannabis-based 
medicines only produce few side effects (Rog et al., 2005; Aragona et al., 2009), self-medication may lead to 
dose-dependent decrease in cognitive functioning in MS patients (Honarmand et al., 2011). Myelination 
levels of rats treated with WIN during puberty are akin to those after treatment with vehicle or MDMA. 
Therefore, although puberty is a developmental period highly vulnerable to drug-induced neuronal, 
behavioural and cognitive alterations (Schneider, 2008), chronic treatment with the cannabinoid agonist 
WIN55,212-2 during puberty did not reduce myelination levels. Since the endocannbinoid system is most  
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active during puberty and plays a major role in the maturation process of neurons, presumable neurotoxic 
effects could have been overlaid, or recuperation after treatment occurred. This distinct pattern can be 
observed best when comparing myelination levels in the hippocampal areas (CA 3 and CA 1+2) and the 
median raphe nuclei (Fig.10). Furthermore, rats treated during puberty show a comparable pattern in the 
amygdala; adult-treated rats in the nucleus accumbens shell. Interestingly, brain myelination of MDMA- and 
vehicle-treated animals did not differ in any of the examined regions. Contrary to many human and animal 
studies indicating neurodegenerative properties of MDMA, there was no indication of decreases in 
myelination levels due to chronic MDMA-treatment during either adulthood or puberty. Although gold-chloride 
staining is a fast and effective method to investigate myelination levels (Wahlsten et al., 2003), it is not 
without limitations. Staining intensity can vary between the samples, and arbitrary definition of the threshold 
reduces the reliability of this method. Furthermore, staining of white matter is universal, therefore no 
conclusions about damage to unmyelinated fibers, or functional alterations can be drawn. However, the 
present results point to three indications which deserve further investigation: 1. MDMA+WIN treatment 
robustly reduces myelination levels. 2. MDMA administration alone does not change myelination levels. Both 
1. and 2. are age- independent effects. 3. WIN reduced myelination levels in adult-, but not pubertally treated 
rats.   
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General discussion 
 
Drug abuse and its consequences contribute to enormous costs in terms of health care and social 
welfare. However, underlying mechanisms and effects of two of the most commonly consumed 
illicit recreational drugs world wide, namely ecstasy (MDMA) and cannabis, are still not fully 
understood. Most ecstasy users are young adults as well as polydrug users, and the majority 
concomitantly consumes cannabis. Consumption of cannabis, especially during adolescence, has 
been associated with subsequent consumption of “harder” drugs and addiction and the 
cannabinoid system has been implicated in the reinforcing properties of psychostimulant drugs. 
Activation of cannabinoid receptors in the brain influences various neurotransmitter systems by 
inhibiting neurotransmitter release, thus potentially modulating the effect MDMA has on 5-HT 
transmission and resulting behaviour.  
 
This thesis set out to investigate effects of these drugs on cognition and behaviour in rats. The 
Review examined the state of knowledge regarding polydrug use (MDMA+cannabis or cannabinoid 
agents). Acute (Study 1) and chronic (Study 2) effects of MDMA, the cannabinoid receptor agonist 
WIN and the combined administration in pubertal and adult rats were investigated. In the following, 
the main findings are summarized and discussed.  
 
MDMA 
 
As expected, acute MDMA administration increased the body temperature and motor activity, and 
decreased food intake. In addition, Study 1 as well as the acute challenge following chronic 
treatment in Study 2 demonstrated an acute influence on decision making: Acutely, MDMA 
induced cost-aversive choice in the effort-based task, indicating immediate alterations on 
decision making cognition. The most likely neurobiological mechanism is the alteration of 5-HT 
and/or DA transmission. MDMA increases extracellular 5-HT levels, particularly in the medial 
prefrontal cortex, the striatum and the hippocampus (Gudelsky and Nash, 1996; Mechan et al., 
2002). 5-HT increase has been shown to reduce choices for high reward-high cost options 
(Homberg, 2012). 
 
 In Study 2, cognitive deficits were evident after long-term administration of MDMA: Chronic 
administration of MDMA induced persistent deficits in recognition memory as well as in 
effort-based decision making. Alterations within brain areas involved in memory and decision 
making processes, such as the hippocampus and ACC are the likely causes of these effects. 
Unexpectedly, locomotor and exploratory behaviours in drug-treated rats were not different from 
controls, indicating MDMA-induced alterations of activity to be acute only. In the additional 
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histological examination, no difference in terms of myelination levels was found between MDMA-
treated rats and controls. Considering the bulk of evidence pointing towards structural alteration 
following chronic MDMA consumption, this result was unexpected. However, recent evidence 
proposes serotonergic dysfunction, rather than structural loss of neurons (Baumann et al., 2007; 
Kivell et al., 2010; Wang et al., 2004). The technique of gold-chloride staining only assesses white 
matter, thus structural changes in grey matter or functional alterations of neurotransmission are not 
asserted. Both acute and chronic administrations of MDMA lead to behavioural as well as cognitive 
changes. Therefore, lack of alterations of involved brain areas is quite unlikely and should be 
assessed using other methods. 
 
WIN55,212-2 
 
In earlier studies, systemic and intracerebral administration of the cannabinoid receptor agonist 
WIN55,212-2 induced dose-dependent alterations in motor activity, prepulse inhibition, operant 
behaviour and social interaction (Drews et al., 2005; Schneider et al., 2008; Wegener et al., 2008). 
In the present studies, systemically administered WIN did not alter decision making or the majority 
of the behavioural patterns examined. Acutely, WIN administration lead to an unexpected 
increase of body temperature. Furthermore, it had no effect on food intake or motor activity. 
This contrasts with studies finding dose-dependent alterations of locomotion, hypothermia and 
hyperphagia in response to CB1 receptor agonists (Kirkham, 2005; Taffe, 2012; Razdan, 1986; 
Little et al., 1988). This discrepancy can be explained by differences in dosage, route of 
administration, species, rat strains and substances used (see below).  
 
Interestingly, various studies suggest lasting impairments in learning and memory in response to 
chronic treatment with WIN (Abush and Akirav, 2012) or THC (Steel et al., 2011). However, in the 
present study administered chronically, WIN did not induce memory deficits or impairments 
of decision making. Considering the frequency of administration and the long half-life of 
cannabinoids, the dose of WIN was realistically high.  
 
Although all chronically treated animals showed a behavioural profile indistinguishable from 
controls, age-related differences in myelination levels were observed, indicating reduced 
myelination in adult, but not pubertal rats. Whether this is due to neurotoxic properties of long-term 
administration of WIN (Sarne and Mechoulam, 2005), or increased white matter due to CB1 
activation during puberty, remains elusive. 
 
WIN55,212-2 is one of the most widely used and well established synthetic cannbinoid agonist. Its 
systemic administration to animals mimics exogenous cannabinoid actions more closely than 
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restricted local application. WINs pharmacological, cognitive and physiological effects resemble, 
though are not identical to, those of THC. However, some disadvantages of experimental 
application appear. First, it binds to both CB1 and CB2, and to CB2 with a slightly higher affinity 
(Pertwee, 2008).  By comparison, THC binds equally to CB1 and CB2 receptors, and has less 
efficacy at the latter. WIN elicits cannbinoid-like effects (antinociception, hypoactivity) 
independently of CB1 receptors, making differentiation of its effects on the brain and the periphery 
difficult. Second, exogenous cannabinoids have a distinct selective profile of pharmacological 
action within the brain and body compared to endogenous cannbinoids, which have been shown to 
activate vanilloid transient receptor potential (TRPV1) receptors and GPR55 in addition to CB1 and 
CB2 (Pertwee, 2008; Pertwee, 2010). Therefore, WIN has to be considered as a somewhat limited 
pharmacological agent.  
 
MDMA & WIN 
 
The results of Study 1 demonstrate that the cannabinoid receptor agonist WIN has little influence 
on MDMA-induced impairments in decision making, increased body temperature and locomotion 
when administered acutely. The only exception, attenuation of MDMA-produced anxiolytic 
behaviour, was neither statistically clear or obtained from an explicit anxiety  test. In other words, 
acute co-consumption of a cannabiniod receptor agonist does not seem to counteract 
MDMA-produced effects. Rather, behavioural and cognitive effects seen following co-
administration were similar or more pronounced, indicating additive negative effects.  
 
Retrospective studies involving human long-term polydrug users reveal inconsistent results. Some 
attribute impairments in decision making and memory to MDMA use, others hold cannabis 
responsible. General agreement is reached regarding additive negative consequences of chronic 
MDMA+cannabis consumption on decision making and memory (Schulz, 2011). In contrast, Study 
2 demonstrates a task-dependent influence on cognition: whereas chronic co-administration of 
WIN reversed MDMA-produced deficits in working memory, there was no interaction in 
terms of effort-based choice, body weight, or locomotion. Cannabis-independent deficits in 
executive functions such as decision making in long-term MDMA users has been demonstrated by 
several human studies (Morgan et al., 2006; Quednow et al., 2007), and further supports the notion 
of a limited interaction of these substances to certain brain regions. 
 
Additional histological examination of myelination suggests that there is no attenuation of 
presumed MDMA-induced neurotoxicity by WIN. On the contrary, chronic MDMA+WIN 
administration robustly resulted in low myelination levels in all brain regions examined compared to 
the control group, and this result was evident for both adult as well as pubertal rats. 
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Future studies could narrow down the mechanism and site of interaction by 1) co-administering 
specific CB1 agonists or cannabinoid transporter inhibitors, 2) microinject WIN or a cannabionoid 
receptor agonist into the hippocampus while administering MDMA systemically and 3) examine 5-
HT content or more conclusive markers for neurotoxicity after chronic co-administration. 
 
Conclusion 
 
This thesis provides the first account of effects of MDMA in an animal model of decision making. 
Both acute and chronic administrations lead to impairments in effort-based choice. No apparent 
structural alterations in the brain in terms of myelination were found, however the method is limited 
to white matter and thus functional changes, especially within the 5-HT system, cannot be 
excluded. Furthermore, reports of memory deficits in long-term MDMA users could be supported. 
Overall, detrimental consequences of acute and chronic MDMA administration were observed, 
which support findings of reduced cognitive capacity in long-term human MDMA users and indicate 
immediate reductions in decision making ability. 
 
The minimal effects of WIN on cognition or behaviour, despite possible alterations on a cellular 
level as indicated by diminished myelination for chronically treated adult rats, was somewhat 
unexpected. However, differences between the synthetic CB receptor agonist and exogenous 
cannabinoids found in cannabis exist, and make direct comparisons difficult. At the same time, 
having equal (null) effects as the vehicle group on decision making tasks demonstrate WIN-only 
administration to be an appropriate control and adds value to the restricted interaction with MDMA 
on memory. 
 
Study 2 implements an animal model of chronic (co-)administration of MDMA and a cannabinoid 
agonist, thereby adding to the knowledge about long-term effects of these drugs on cognition and 
behaviour in adult and pubertal rats. The only interaction of WIN with MDMA was observed after 
chronic treatment in the object recognition memory task. Otherwise, no modulatory action of CB1 
stimulation on MDMA- induced impairments was evident.  
 
With exception of the impairments in recognition memory, adult rats seemed to be more sensitive 
to the impairments induced by MDMA and MDMA+WIN administration. However, pubertally treated 
rats were not unaffected, and functional brain changes cannot be ruled out. 
Generalization of these results to human drug users is limited due to differences in doses ingested, 
route of administration and metabolism. However, if any conclusion can be derived for human 
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MDMA users, it should be noted that co-consumption of cannabinoid agents does not seem to 
reduce, but probably exacerbates, MDMA-induced impairments. 
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Deutsche Zusammenfassung  
Einleitung 
 
MDMA (3,4-methylenedioxymetamphethamin, “Ecstasy”) ist eine der meist verbreiteten illegalen 
Drogen. Allerdings ist der Einfluss von sowohl akutem wie auch chronischem Konsum auf 
kognitive Funktionen wie Gedächtnis und Entscheidungsverhalten, sowie die den physiologischen 
und psychologischen Effekten zugrunde liegenden neurobiologischen Mechanismen noch nicht 
vollständig geklärt. Des Weiteren wird unter Forschern debattiert, ob und in welchem Ausmaß 
MDMA neurotoxische Wirkung besitzt.  
MDMA ist ein synthetisches Amphetaminderivat, welches 1912 als Nebenprodukt der Herstellung 
eines blutstillenden Medikamentes des pharmazeutischen Konzerns MerckKGaA patentiert wurde 
und heutzutage den Hauptbestandteil von „Ecstasy“ Tabletten ausmacht. Die überwiegend 
innerhalb der „Rave“Kultur eingenommenen Pillen führen zu Euphorie, Empathie, Energie sowie 
pro-sozialen Empfindungen. Negative Wirkungen sind unter anderem Hyperthermie, stark erhöhte 
Herzschlagrate und Blutdruck, Schwitzen, Schlaflosigkeit und depressive Verstimmung sowie 
Angst und Konzentrationsschwierigkeiten während des „come downs“. Auch 
Langzeitbeeinträchtigungen von z. B. Gedächtnisleistung und Entscheidungsverhalten wurden 
bereits in Studien mit MDMA Konsumenten gezeigt. Eine große Rolle spielt hierbei die durch 
MDMA hervorgerufene erhöhte Ausschüttung und Wiederaufnahmehemmung der monoaminen 
Neurotransmitter Serotonin (5-HT), Dopamine (DA) und Noradrenaline (NA). Desweiteren könnte 
häufige und/oder andauernde MDMA Gabe zu spezifischer Neurotoxizität (bzw. 
strukturellen/funktionalen Veränderungen) auf serotonerge Axonterminale in frontalen 
Gehirnarealen führen.  
Die Mehrheit der Ecstasykonsumenten sind junge Erwachsene, und fast alle (90-98%) nehmen 
begleitend andere Drogen, hauptsächlich Cannabis. 
 
Cannabis ist die am häufigsten konsumierte illegale psychoaktive Droge weltweit. Produkte der 
Hanfpflanze (Cannabis sativa/indica) werden schon seit Jahrtausenden für industrielle und 
medizinische Zwecke verwendet. Aufgrund neuroprotektiver sowie entzündungshemmender 
Eigenschaften wird derzeit die medizinische Anwendung von (synthetischen) Cannabisprodukten 
erforscht; hauptsächlich wird Cannabis aber als Droge konsumiert. Die Herauslösung des 
psychoaktiven Hauptbestandteils von Cannabis, delta9-Tetrahydrocannabinol (∆9-THC, THC) im 
Jahr 196vier führte zur Entdeckung des endocannabinoiden Systems, welches endogene 
Cannabinoide und deren Rezeptoren einschließt. Aktivierung von cannbinoiden Rezeptoren, 
speziell Typ1 (CB1) im zentralen Nervensystem trägt maßgeblich zur Steuerung von 
Reizweiterleitung bei; größtenteils findet eine Hemmung der Ausschüttung von GABA, Glutamat, 
5-HT, DA und NA statt. Die Wirkung von Cannabis umfasst, abhängig vom THC Gehalt, 
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Stimulation, milde Euphorie, Entspannung, erhöhte sensorische Wahrnehmung, reduziertes 
Schmerzempfinden und Appetitsteigerung. Sowohl akut als auch nach mehrfachem Konsum 
können negative Effekte wie Verschlechterung der Kurzzeit- und Arbeitsgedächtnisleistung, 
Konzentration, Aufmerksamkeit, motorische Beeinträchtigung, und psychotische Symptome 
entstehen. Studien mit Cannabis Konsumenten sowie Verabreichung von cannabinoiden 
Substanzen an Labortiere zeigten strukturelle und funktionale Veränderungen in bestimmten 
Gehirnarealen, z. B. im Hippocampus, welcher mit Lernen und Gedächtnis assoziiert ist. Obwohl 
Cannabisprodukte generell als „weiche Drogen“ wahrgenommen werden, und ihre medizinische 
Nutzung voranschreitet, wurden Beeinträchtigungen kognitiver Leistung sowie langzeitliche 
Veränderungen im Gehirn, vor allem nach längerem und schwerem Konsum, nachgewiesen.  
Die psychopharmakologische Forschung hat sich sowohl mit MDMA als auch Cannabis beschäftigt 
- dagegen sind Studien zu Co-Konsum spärlich. Bisherige Ergebnisse deuten auf einen 
modulierenden Einfluss akuter Verabreichung von cannabinoiden Agonisten auf MDMA-induzierte 
Verhaltensweisen hin, während chronischer Co-Konsum womöglich zu zusätzlichen 
Beeinträchtigungen führt. Allerdings sind (Langzeit)Studien in Tiermodellen, welche den Einfluß 
der jeweiligen Substanz alleine und/oder in Kombination auf Verhaltens- und Gedächtnisleistung 
sowie kognitive Funktionen testen, rar. 
 
Die vorliegende Arbeit untersucht den Einfluß von MDMA und dem synthetischen cannabinoiden 
Rezeptor Agonist WIN55,212-2 (WIN), auf verschiedene Formen des Entscheidungsverhaltens, 
Gedächtnisleistung, physische Aktivität und physiologische Parameter wie Körpertemperatur und 
Fressverhalten. Innerhalb eines sowohl akuten als auch chronischen systemischen 
Verabreichungsmodell werden die Effekte beider Substanzen einzeln und in Kombination getestet, 
um Co-Konsum zu simulieren und interaktive Reaktionen festzustellen. Innerhalb der chronischen 
Behandlung werden adulte sowie pubertäre Tiere und der Myelinisierungsgrad der zugehörigen 
Gehirne untersucht, um etwaige vulnerable Perioden für Drogenkonsum oder altersabhängige 
Unterschiede festzustellen. 
 
Review 
 
In “MDMA & Cannabis: A Mini-Review of Cognitive, Behavioral, and Neurobiological Effects of Co-
consumption” untersuchte ich 23 kürzlich veröffentlichte Studien (zwischen 2002 und 2010), 
welche sich mit der Auswirkung einer Kombination von MDMA und Cannabis oder cannabinoiden 
Substanzen auf kognitive Funktionen, Verhalten, und neurobiologische Interaktionen befassen. 
Humanstudien zu kognitiven Funktionen ergeben ein uneinheitliches Bild. Einige zeigen eine 
Cannabis-abhängige Verringerung der Gedächtnisleistung, und schreiben MDMA Konsum Defizite 
in Lern- und Entscheidungsverhalten, sowie kognitiver Kontrolle zu. Andere bestätigen einen 
additiven negativen Effekt gleichzeitiger Einnahme. Eine Möglichkeit, die diskrepanten Ergebnisse 
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zu erklären ist, dass die Menge und Häufigkeit von begleitendem Cannabiskonsum für die 
Ausprägung der durch MDMA hervorgerufenen Schwierigkeiten entscheidend sein kann. 
Allerdings erschweren unterschiedliche Einschlusskriterien (Menge und Häufigkeit des MDMA 
Missbrauchs, Zeitraum der Abstinenz, Konsum weiterer Drogen) und Kontrollgruppen (Cannabis 
Konsum einschließend oder ausschließend, abstinente oder naive MDMA User) eindeutige 
Vergleiche oder Resultate. Die meisten Forschungsarbeiten involvieren Langzeit- „Polydrug“-
Konsumenten und sind retrospektiver Natur, während Tierstudien, welche chronischen Co-Konsum 
modellieren, spärlich sind. In akuten Tiermodellen hingegen wurde z. B. ein regulativer Effekt des 
cannabinoiden Systems auf die verstärkende/belohnende Wirkung von MDMA, sowie eine Störung 
des Arbeitsgedächtnisses bzw. Aufhebung der durch MDMA verursachten Defizite im 
Wiedererkennungstest, bei gleichzeitiger Gabe gezeigt. Diese Studien deuten auf eine Interaktion 
zwischen veränderter Neurotransmission durch MDMA, speziell der Wirkung auf das serotonerge 
System, und Aktivierung cannabinoider Rezeptoren im Hippocampus hin. Des weiteren wurden in 
Tierstudien und Zellkulturen modulierende Effekte von akuter Co-Gabe cannabinoider Liganden 
auf MDMA-induzierte Veränderungen der Körpertemperatur, Aktivität, und Neurotoxizität gezeigt. 
 
Studie 1 
 
“Acute Co-administration of the Cannabinoid Receptor Agonist WIN55-212,2 does not influence 
3,4-methylenedioxymetamphetamine (MDMA)-induced Effects on Effort-based Decision making, 
Locomotion, Food intake and Body temperature“ untersucht Existenz und Ausmaß der akuten 
Wechselwirkung von MDMA (7.5mg/kg, s.c.) und WIN (1.2mg/kg, i.p.) bei verschiedenen 
Verhaltensweisen. Die Wirkung dieser Substanzen auf die kognitive Fähigkeit des 
Entscheidungsverhaltens wurde mittels dem Aufwands-basiertem („effort-based“) Paradigma in 
einem T-Labyrinth geprüft. Sowohl MDMA als auch MDMA+WIN Verabreichung führte zu einer 
Verringerung der Entscheidungen für den hohen Aufwand-hohe Belohnung-Arm und der 
Nahrungsaufnahme und zu einer Steigerung der motorischen Aktivität sowie der Exploration 
(Anzahl der Aufrichtungen), während WIN hier keinen Effekt hervorrief. WIN induzierte eine 
unerwartete kurzfristige Erhöhung der Körpertemperatur, während sowohl MDMA als auch 
MDMA+WIN erst eine Stunde nach den Verhaltenstests einen signifikanten Anstieg produzierten. 
Die einzige (instabile) Interaktion fand sich im Open Field: MDMA führte zu angstähnlichen 
Verhalten, welches durch Co-Administration von WIN verringert wurde. Die zugrunde liegenden 
neurobiologischen Mechanismen dieser Effekte bleiben spekulativ. Allerdings zeigen die 
Ergebnisse, dass akute MDMA Gabe über die bekannten physiologischen Veränderungen 
(Hyperthermie, erhöhte Aktivität, verringerter Appetit) hinaus auch sofortige Beeinträchtigungen 
bestimmter kognitiver Funktionen, nämlich Entscheidungsverhalten, hervorruft. Ingesamt hatte 
akute Co-Administration von WIN kaum modulierende Wirkung auf MDMA-induzierte 
Verhaltensweisen. 
Deutsche Zusammenfassung 
 
 
81 
Studie 2 
 
In “Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or 
adulthood reverses 3,4-methylenedioxymetamphetamine (MDMA)-induced deficits in recognition 
memory but not in effort-based decision making“ werden die Effekte chronischer Verabreichung 
von MDMA (7.5mg/kg, s.c.) und WIN (1.2mg/kg, i.p.), alleine oder in Kombination, an adulten 
(postnataler Tag (PT) >80) oder pubertären (PT 40-65) Ratten untersucht. Nach 25 Tagen 
irregulärer Behandlung zeigten alle MDMA-behandelten Tiere deutliche Defizite im 
Objektwiedererkennungstest, einer Aufgabe mittels derer das Kurzzeitgedächtnis getestet wird. 
Diese Beeinträchtigung war bei pubertären Tieren vier Wochen später noch vorhanden. In der 
Gruppe, welche MDMA+WIN erhielt, wurde keine solche Verringerung der Gedächtnisleistung 
gemessen. Des weiteren benötigten sowohl MDMA als auch MDMA+WIN, aber nicht WIN-
behandelte adulte Tiere mehr Zeit um optimales aufwands-basiertes („effort-based“) 
Entscheidungsverhalten wiederzuerlernen. Innerhalb der Tiergruppe, welche während der Pubertät 
behandelt wurde, zeigten sich dagegen keine Unterschiede. In einer weiteren Form des 
Entscheidungsverhaltens, dem verzögerungsbasiertem (“delay-based“) Paradigma, waren nach 
chronischer Verabreichung keinerlei Differenzen erkennbar. Darüber hinaus zeigten alle vier 
Behandlungsgruppen unabhängig vom Alter ähnliche motorische Aktivität und 
Explorationsverhalten sowohl kurz nach Beendigung der chronischen Gabe als auch vier Wochen 
später. Während der Behandlung mit MDMA und MDMA+WIN zeigten pubertäre Ratten 
verringerte Gewichtszunahme; WIN hatte hier keinen modulierenden Effekt. Zusammenfassend 
läßt sich sagen, dass chronische MDMA Gabe robuste Langzeitdefizite in Gedächtnisleistung 
produziert. Dieser Effekt gründet sich mutmaßlich auf veränderte (serotonerge) Neurotransmission 
und kann durch chronische Stimulation des CB1 Rezeptors aufgehoben werden. Die Interaktion 
auf neuronaler Ebene ist höchstwahrscheinlich im Hippocampus lokalisiert, wohingegen scheinbar 
keine Verbesserung von MDMA-induzierten Störungen in präfrontalen Hirngebieten, welche 
komplexere Aufgaben wie Entscheidungsverhalten steuern, stattfindet. 
 
Fazit  
 
MDMA 
Diese Arbeit beschreibt das erste Rattenmodell zu Entscheidungsverhalten unter dem Einfluß von 
MDMA. Sowohl akute als auch chronische Verabreichung führte zu einer Verschlechterung der 
aufwandsbasierten Wahl. Zwar wurden keine strukturellen Veränderungen im Gehirn 
(Myelinisierungsgrad) gemessen, allerdings ist diese Färbemethode auf das Erkennen von weißer 
Substanz (Axone) begrenzt. So können funktionale Abweichungen, vor allem innerhalb des 5-HT 
Systems, nicht ausgeschlossen werden. Desweiteren wurde nach Langzeitkonsum von MDMA ein 
robustes Defizit in Gedächtnisleistung gezeigt. Insgesamt wurden nachteilige und nachhaltige 
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Konsequenzen von chronischer MDMA Gabe gezeigt, welche somit Ergebnisse von Humanstudien 
validieren, welche reduzierte kognitive Fähigkeiten bei (langzeit-) MDMA Konsumenten fanden. 
Zusätzlich weist Studie 1 auf eine sofortige Reduzierung der Fähigkeit, optimale Entscheidungen 
zu treffen, nach akutem MDMA Konsum hin.  
 
WIN 
Die Verabreichung von WIN führte zu unerwartet wenigen Verhaltensänderungen, trotz 
verringerter Myelinisierung in verschiedenen Gehirnbereichen bei chronisch behandelten adulten 
(jedoch nicht pubertären) Ratten. Allerdings existieren Differenzen zwischen diesem synthetischen 
cannabinoid Rezeptor Agonisten und exogenen Cannabinoiden, wie sie in Cannabis vorkommen, 
daher ist eine Generalisierung der Ergebnisse schwierig. Gleichzeitig unterstützt das Ausbleiben 
eines WIN-induzierten Effektes auf Entscheidungsverhalten die Rolle des CB1 Rezeptor Agonisten 
als Kontrolle bzw. modulierende Substanz ohne eigene Wirkung auf diese kognitiven Funktionen. 
Daher wird die eingeschränkte Interaktion mit MDMA auf Gedächtnisleistung um so bedeutsamer. 
 
MDMA+WIN 
In Studie 2 wird ein Tiermodell zur chronischen (Co)-Gabe von MDMA und einem cannabinoiden 
Agonisten eingeführt. Hiermit wurde das Wissen um die Langzeiteffekte dieser Substanzen auf  
Verhalten und Kognition in adulten und pubertären Ratten erweitert. Da die einzige Interaktion von 
WIN mit MDMA innerhalb des Gedächtnistests deutlich wurde, konnte der Hippocampus als eine 
vulnerable Gehirnregion bestätigt werden. Anderweitig wurden keine modulierenden Effekte der 
MDMA-induzierten Beeinträchtigungen durch CB1 Stimulation gemessen. Mit Ausnahme der 
Verschlechterung im Wiedererkennungstest scheinen adulte Ratten sensibler auf durch MDMA 
und MDMA+WIN Verabreichung hervorgerufene Defizite zu reagieren.  Andererseits waren Ratten, 
die während der Pubertät behandelt wurden, ebenfalls betroffen, und funktionale Schäden im 
Gehirn zusätzlich zu der Verringerung des Myelinisierungsgrades können nicht ausgeschlossen 
werden. 
 
Eine Generalisierung dieser Ergebnisse auf menschliche Drogenkonsumenten scheint nicht 
angemessen, da die Unterschiede, z. B. in Dosierung, Art der Verabreichung, und Metabolismus 
zu groß sind. Falls ein Rückschluß gezogen werden sollte, läßt sich höchstens feststellen, daß Co-
Konsum eines cannabinioden Stoffes MDMA-induzierte Beeinträchtigungen nicht reduziert, 
sondern wahrscheinlicher, verschlimmert. 
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